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ABSTRACT 
Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer with a 
poor prognosis. Currently, prognosis for HCC patients remains poor as few therapies are 
available. The clinical need for more effective HCC treatments remains unmet partially 
because HCC is genetically heterogeneous and HCC driver genes amenable to targeted 
therapy are largely unknown. Mutations in the TP53 gene are found in ~30% of HCC 
patients and confer poor prognosis to patients. Identifying genes whose depletion can 
inhibit HCC growth, and determining the mechanisms involved, will aid the development 
of targeted therapies for HCC patients. Therefore, the first half of this thesis focuses on 
identifying genes that are required for cell growth in HCC independent of p53 status.  
We performed a kinome-wide CRISPR screen to identify genes required for cell 
growth in three HCC cell lines: HepG2 (p53 wild-type), Huh7 (p53-mutant) and Hep3B 
(p53-null) cells. The kinome screen identified 31 genes that were required for cell growth 
in 3 HCC cell lines independent of TP53 status. Among the 31 genes, 8 genes were 
highly expressed in HCC compared to normal tissue and increased expression was 
associated with poor survival in HCC patients. We focused on TRRAP, a co-factor for 
histone acetyltransferases. TRRAP function has not been previously characterized in 
HCC. CRISPR/Cas9 mediated depletion of TRRAP reduced cell growth and colony 
formation in all three cell lines. Moreover, depletion of TRRAP reduced its histone 
acetyltransferase co-factors KAT2A and KAT5 at the protein level with no change at the 
mRNA level. I found that depletion of KAT5, but not KAT2A, reduced cell growth. 
Notably, inhibition of proteasome- and lysosome-mediated degradation failed to rescue 
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protein levels of KAT2A and KAT5 in the absence of TRRAP. Moreover, tumor 
initiation in an HCC mouse model failed after CRISPR/Cas9 depletion of TRRAP due to 
clearance via macrophages and HCC cells depleted of TRRAP and KAT5 failed to grow 
as subcutaneous xenografts in vivo. RNA-seq and bioinformatic analysis of HCC patient 
samples revealed that TRRAP positively regulates expression of genes that are involved 
in mitotic progression. In HCC, this subset of genes is clinically relevant as they are 
overexpressed compared to normal tissue and high expression confers poor survival to 
patients. I identified TOP2A as one of the mitotic gene targets of the TRRAP/KAT5 
complex whose inhibition greatly reduces proliferation of HCC cells.   
Given that this was the first time the TRRAP/KAT5 complex has been identified 
as a therapeutic target in HCC, the second half of this thesis focuses on identifying the 
mechanism via which depletion of this complex inhibits proliferation of HCC cells. I 
discovered that depletion of TRRAP, KAT5 and TOP2A reduced proliferation of HCC 
cells by inducing senescence. Typically, senescence is an irreversible state of cell cycle 
arrest at G1 that is due to activation of p53/p21 expression, phosphorylation of RB, and 
DNA damage. Surprisingly, induction of senescence after loss of TRRAP, KAT5 and 
TOP2A arrested cells during G2/M and senescence was independent of p53, p21, RB and 
DNA damage.  
In summary, this thesis identifies TRRAP as a potential oncogene in HCC. I 
identified a network of genes regulated by TRRAP and its-cofactor KAT5 that promote 
mitotic progression. Moreover, I demonstrated that disruption of TRRAP/KAT5 and its 
downstream target gene TOP2A result in senescence of HCC cells independent of p53 
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status. Taken together, this work suggests that targeting the TRRAP/KAT5 complex and 
its network of target genes is a potential therapeutic strategy for HCC patients.  
 vi 
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CHAPTER I 
Introduction 
 
Hepatocellular Carcinoma 
Liver cancers are the fourth most common cause of cancer related deaths 
worldwide (1). Primary liver cancers are comprised of distinct histopathological subtypes 
including Hepatocellular Adenoma (HCA), Hepatocellular Carcinoma (HCC), 
Intrahepatic Bile Duct Carcinoma (cholangiocarcinoma or CCC), Hepatoblastoma and 
Hemangiosarcoma (2). HCC is the most common and prevalent subtype, comprising 
>83% of liver tumors. The number of new cases of HCC in the United States has 
increased by ~60% over the last 20 years (from 5.4 to 8.6 new cases per 100,000 patients) 
(3). Likewise, the rate of death due to HCC in the United States has also increased by 
~52% (from 4.4 to 6.7 deaths per 100,000 patients) (4).  Overall, HCC has a 5-year 
survival of ~18%, making it the second most lethal tumor type, the first being pancreatic 
cancer (5).  
The majority of HCC occurs in patients with underlying liver disease. These 
diseases include chronic infection with Hepatitis B virus (HBV) or Hepatitis C virus 
(HCV), chronic alcohol abuse, non-alcoholic steatohepatitis (NASH) and other pro-
inflammatory metabolic diseases (such as hemochromatosis, 1 antitrypsin deficiency 
and tyrosinemia) in combination with obesity. Overall, these etiologies create a pro-
inflammatory environment resulting in hepatic fibrosis. Hepatocytes undergo continuous 
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rounds of death and regeneration in this deleterious setting.  As hepatocytes replicate 
under this stress, they begin to accumulate genetic and epigenetic aberrations (6). This 
genetic and epigenetic instability leads to the initiation of hyperplastic nodules, which 
can progress to malignancy.  
Hyperplastic nodules are comprised of regenerating hepatocytes and show normal 
cytological features; however, these nodules can proceed to dysplastic nodules. 
Dysplastic nodules are considered to be a pre-malignant lesion for HCC.  Dysplastic 
nodules show abnormal cytological features such as cellular atypia, pseudoglandular 
structures and evidence of increased stromal invasion (2). Dysplastic nodules may 
eventually evolve to form invasive hepatocellular carcinomas. 
 
Molecular Characterization  
Molecular analysis of human HCC has revealed multiple genetic and epigenetic 
alterations that are associated with activation of oncogenes and inhibition of key tumor 
suppressor genes. Mutations in the TERT promoter are the most common genetic 
aberration seen in HCC samples. These mutations (which include amplifications) account 
for ~60% of HCC cases and can be detected in dysplastic nodules (7). The prevalent 
theory in the field of HCC genomics postulates that the high presence of TERT promoter 
mutations in HCC is potentially due to viral integration secondary to HBV and HCV 
infection. Mutations in pathways that regulate cell cycle progression such as TP53, WNT 
signaling, chromatin remodeling , or angiogenesis account for a large number of HCC 
cases (6). Chromosomal instability (CIN), as assayed by fluorescence-in-situ 
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hybridization (FISH), demonstrated that CIN can appear in benign lesions but is more 
frequent in high-grade dysplastic nodules and correlates with HCC tumor progression (8).  
Aberrations in pathways responsible for cell cycle progression account for ~30% 
of HCC cases. These aberrations include mutations in TP53, 
overexpression/amplification of CCND1/FGF19 and silencing of RB1 expression via 
deletion or promoter methylation (7, 9). Mutations in the tumor suppressor CDKN2A are 
also seen in ~5% of HCC cases and are associated with alcohol abuse (10).  
WNT pathway alterations include activating mutations in the β-catenin gene 
(CTNNB1) and inactivating mutations in AXIN1. These mutations are seen in 30% and 
10% of HCC cases, respectively (6). In addition, promoter hypermethylation of the APC 
tumor suppressor is also seen in a small subset ~3% of HCC (11). Overall, WNT pathway 
mutations are rarely seen in dysplastic nodules and are thought to occur later during HCC 
progression. In terms of correlation with HCC risk factors, CTNNB1 activating mutations 
are associated with alcohol abuse (11).  
Loss of function mutations in chromatin remodelers such as ARID1A and ARID2 
account for ~10% and ~5% of HCC cases respectively (6). Interestingly, mutations in 
ARID1A and ARID2 were enriched in non-HBV and non-HCV populations (12) 
suggesting a tumor suppressor role of the SWI/SNF complex in non-viral induced HCC. 
In line with this, a previous study demonstrated that suppression of ARID1A in 
hepatocytes promotes fatty liver and steatohepatitis (13) 
Finally, amplification of genes required for angiogenesis and growth such as 
VEGFA account for ~5-10% of HCC cases (6, 14). Amplifications in VEGFA are seen 
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more commonly in HCC compared to dysplastic nodules (7). Interestingly, dysplastic 
nodules receive their vascular supply through the portal system whereas HCC receives its 
vascular supply from the hepatic artery (2). The role of VEGFA in promoting tumor 
growth is well established ubiquitously in cancer models. However, given the difference 
in vascular supply in HCC compared to dysplastic nodules it would be interesting to 
examine if VEGFA amplifications promote “rewiring” from the portal system to the 
hepatic artery during progression from a dysplastic nodule to HCC.  
 Epigenetic aberrations are also seen in HCC. DNA methylation profiles between 
HCC and normal tissue revealed 298 genes which were significantly hypermethylated. 
These genes were involved in differentiation, stem cell maintenance and were targets of 
the Polycomb repressive complex (14).  
 
Molecular Subclasses of HCC 
As our understanding of HCC genomics has advanced, multiple attempts have 
been made to identify genetic signatures and use these signatures to cluster HCC patients 
in order to provide prognostic information. 
Profiling of 603 HCC patient tumors from 8 independent patient cohorts revealed 
three major classes which correlated with tumor size, extent of cellular differentiation, 
and serum alpha-fetoprotein levels—S1, S2 and S3 (15). Tumors within the S1 class had 
DNA mutations mainly in the TP53 tumor suppressor gene and contained genetic 
signatures associated with TGF- activation. Tumors within the S2 class also contained 
TP53 mutations, however tumors within this class were positive for the stem-like features 
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such as EPCAM and had increased expression of alfa-fetoprotein (AFP). Furthermore, S2 
tumors contained genetic signatures associated with activated Insulin Like Growth Factor 
2 (IGF2). Interestingly, tumors within both S1 and S2 classes contained genetic 
signatures associated with activated WNT signaling (15). However there was no 
detectable activating CTNNB1 mutation in these samples suggesting the presence of 
additional cellular programs that activate WNT signaling. The authors attributed this 
observation to crosstalk from activated TGF- signaling. Both S1 and S2 tumors are 
histologically less differentiated and patients have high rates of recurrence. Finally, S3 
tumors are driven by CTNNB1 mutations, are histologically more differentiated and have 
lower rates of recurrence. In this classification regimen, patients with S3 tumors had 
greater survival rates than patients with S1 and S2 tumors (16). Collectively, S1 and S2 
tumors are grouped into the ‘proliferative’ class whereas S3 tumors are in the ‘non-
proliferative’ class (17). 
Nearly a decade after the release of this classification scheme, groups are now 
beginning to test whether these classes are predictive of responses to therapies. For 
example, by classifying immortalized HCC cell lines into this system, groups were able 
to demonstrate that S2 HCC cell lines were more sensitive to drugs like JQ1 (18) and the 
FGFR inhibitors BGJ398 and AZD4547 (19). Of note, out of 25 HCC cell lines validated 
in vitro, no HCC cell line tested corresponded to the S3 tumor subtype (18). The 
predictive power of the S1, S2 and S3 subclasses on response to therapies in HCC 
patients remains to be seen. Moreover, although this classification scheme was one of the 
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first to molecularly characterize HCC tumors, it failed to consider aberrations in copy 
number, epigenetic changes and the presence of tumor immune infiltrates.   
More recently, analysis of HCC tumor samples by The Cancer Genome Atlas 
(TCGA) group by whole-exome sequencing, DNA copy number analyses, and DNA 
methylation along with analysis of miRNA and proteome expression revealed three 
clusters that were not originally captured by in the S1, S2, S3 classification scheme (14).  
iCluster 1 contained high grade tumors that were poorly differentiated. Of note, the 
prevalence of TERT promoter amplifications was low, but these tumors had silenced the 
miR-122a locus. iCluster 2 contained low grade tumors with less microvascular invasion 
and had high levels of CDKN2A inactivation and high incidence of CTNNB1 mutations. 
iCluster 3 contained low grade tumors with less microvascular invasion but also 
displayed high amounts of chromosomal instability. These tumors contained TP53 
mutations and had high prevalence of TERT promoter mutations. Immune phenotyping of 
HCC revealed that a subset of HCC had high levels of immune cell infiltration. However, 
the composition of the infiltrate did not correlate with HBV/HCV infection or patient 
survival. Like the S1, S2, S3 classifications, it remains to be seen whether the iCluster 
classifications are predictive of responses to therapies.  
 
Clinical Management 
Management of patients with HCC is divided into surgical and clinical 
management. Surgical intervention is available for patients with early stage disease. 
Patients who present with a solitary nodule (<3cm in size) will qualify for surgical 
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resection whereas patients with 2-3 small nodules (<3cm in size) will qualify for liver 
transplantation (20). Surgical resection is associated with a survival rate of ~60% after 5 
years, however, ~ 70% of these patients have tumor recurrence at 5 years (21). In 
contrast, transplantation is associated with a survival of ~60-80% after five years and 
50% after 10 years. Furthermore, the tumor recurrence rate is <15% after 5 years (6). 
However, given the large deficit between the demand for and supply of donors, there is a 
need for alternative therapies while patients wait for transplants.  
Ablation therapy provides one such alternative. Ablation therapy utilizes targeted 
radiofrequency waves in order to induce necrosis by increasing the intra-tumoral 
temperature.  This form of therapy is utilized in patients with single nodules that are large 
(>3cm) in size (22). Currently, there are no studies that compare outcomes with surgical 
resection, transplantation and radiofrequency ablation for the management of HCC (20). 
However, ablation is frequently used to manage patients who are on the wait-list for 
transplantation. Overall, the only therapies with curative potential available to HCC 
patients are surgical resection, transplantation and radiofrequency ablation (23).  
Non curative therapies consist of transarterial chemoembolization and systemic 
therapies. Patients who have multi-nodal disease without metastasis may qualify for 
transarterial chemoembolization. As discussed earlier, HCC derives its vascular supply 
from the hepatic artery as opposed to the portal system. Transarterial chemoembolization 
involves delivery of a cytotoxic agent directly into the hepatic artery followed 
immediately by embolization of the vessels supply the tumors. The toxic effects on 
normal hepatic tissue from this therapy are low as normal hepatocytes derive their 
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vascular supply from the portal vein. A recent meta-review comparing 101 studies on 
transarterial chemoembolization demonstrated a five-year survival of 32.4% with a 
median survival of 19.4 months and a mortality rate of <1% (24).  
 Systemic therapies are recommended for patients who have metastatic disease or 
those who have progressed after transarterial chemoembolization (6). As our 
understanding of tumor genetics is advancing, targeted therapies are now utilized for 
therapy as they have greater anti-tumor potential and display less toxicity compared to 
cytotoxic agents. However, HCC has the fewest genetic aberrations that can be 
effectively targeted with molecular therapies (6). Hence, there are few targeted therapies 
for HCC. Studies have examined the efficacy of broad-spectrum receptor tyrosine kinase 
(RTK) inhibitors in HCC. In 2008, Sorafenib was the first targeted therapy approved for 
the treatment of HCC. In the hallmark Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol (SHARP) trial, sorafenib increased overall survival from 7.9 
months to 10.7 months compared to placebo (25). Multiple other therapies made it to 
phase 3 clinical trials but failed to show parallel or superior survival results compared to 
sorafenib. These agents include the RTK inhibitors Sunitinib and Erlotinib, the 
Topoisomerase inhibitor, Doxorubicin, and Tivantinib for MET amplified tumors (6). 
More recently, Lenvatinib, a vascular endothelial growth factor (VEGF) and fibroblast 
growth factor receptor (FGFR) inhibitor demonstrated a median overall survival of 13.6 
months (26) and was approved for the treatment of HCC. In addition, Regorafenib was 
approved as second-line treatment after sorafenib as it reduced the risk of death by 37% 
compared to placebo and had a toxicity profile similar to sorafenib (27).  
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In the last year two anti PD-L1 immunotherapies, Pembrolizumab and Nivolumab 
were approved for the treatment for HCC. A phase 2 study with Pembrolizumab showed 
an anti-tumor response in 17% of patient treated with one patient having complete 
remission. Furthermore, 56% of patients showed no disease progression for greater than 
one year (28). A phase 2 study with Nivolumab showed a stable disease rate of 44.9%, 
with 10.2% of these patients achieving a partial response (29). Data from phase 1 trials 
which combine immunotherapy with other targeted therapies are promising (6), but phase 
3 trials are required to fully establish their roles in clinical management. With 
immunotherapies emerging as an additional drug regimen for the treatment of HCC, HCC 
therapeutics is a rapidly growing and exciting field. However, there is still a need to 
identify additional therapeutic targets that show demonstrable anti-tumor potential 
beyond RTK inhibitors. 
 
Cell Cycle Primer 
 The mammalian cell cycle is organized into four major phases: G0/G1, S, G2 and 
M. Proliferation is dependent on progression through these phases. Moreover, 
progression through the phases can be induced by extracellular signals such as mitogenic 
factors and intracellular signals such as DNA damage (30).  
The G1 phase is characterized by cellular growth and expression of genes 
required for DNA synthesis. During this phase DNA damage is predominantly monitored 
by p53 and checkpoint kinase 2 (CHK2) (30). In order to progress from G1 to S, 
mitogenic signals induce phosphorylation of cyclin D resulting in binding and activation 
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of CDK4/6 (31). Progression from G1 to S is driven by phosphorylation of the 
retinoblastoma protein (RB) and subsequent expression of genes regulated by the E2F 
transcription factor (30). The cyclin inhibitor CDKN1A, also known as P21CIP1, can bind 
to and inhibit the activity of the Cyclin D-CDK4/6 complex (32). Cyclin E, an E2F target 
gene, is expressed at the end of G1 and mediates progression into S phase. The Cyclin 
E/CDK2 complex also phosphorylates Rb thus creating a positive feedback loop to drive 
expression of genes in order to progress into S phase (33).  
S phase is characterized by replication of the genome. During S phase, cyclin E is 
degraded by the ubiquitin proteasome system (34), cyclin A is rapidly synthesized and 
associates with CDK2. In order to faithfully replicate the genome in a timely fashion and 
progress through S phase, the cell monitors for stalled replication forks and DNA damage  
(35). Replication fork stalling can occur via alterations in histone pools, alterations in 
nucleotide pools and decreased chromatin accessibility (35). Furthermore, the cell also 
monitors for DNA damage during replication. The signaling kinases, ataxia-telangiectasia 
mutated (ATM) and ataxia-telangiectasia and RAD3 related (ATR) are the main detectors 
of such lesions (36). Progression through S and into G2 is driven by cyclin A binding to 
CDK1 (33).  
G2 is characterized by rapid cell growth and protein synthesis in order to prepare 
for cell division. Cyclin A is bound to CDK1 and is active until late G2 whereupon 
Cyclin A is replaced by Cyclin B (33). In addition, cells have another opportunity to 
detect and resolve residual DNA damage. DNA damage detected during G2 activates 
checkpoint kinase 1 (CHK1), which induces G2/M arrest via phosphorylation of CDC25 
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(37). Progression from G2 into M is also regulated by polo like kinase 1 (PLK1) and 
aurora kinase A/B (AURKA and AURKB) (38).  AURKA and AURKB regulate activity 
of the Cyclin B/CDK1 complex and also localizes to the centrioles during mitosis to aid 
in cytokinesis (39). During mitosis, CDK1 activity is driven by association with cyclin B. 
Cyclin B is degraded by the anaphase promoting complex (APC) in late mitosis. 
Degradation of cyclin B allows for chromosome separation and cytokinesis mediated by 
microtubules (40). 
 
Targeting Mitosis and the Cell Cycle in HCC 
Cancers are characterized by deregulated proliferation resulting from mutations 
that either hyperactive or inactivate major cell cycle regulators. Furthermore, pathways 
that regulate cell cycle progression are the second most prominent genetic drivers of 
HCC making this network an attractive target for therapeutic intervention. Numerous 
therapeutic strategies have been developed towards targeting cell cycle progression in 
cancer cells. These include microtubule inhibitors, CDK inhibitors, aurora kinase 
inhibitors and agents that induce DNA damage. However, the majority of these strategies 
have failed due to an inefficient therapeutic index or cytotoxic effects on normal cells 
(41).  
 
Cytotoxic Agents and DNA Damage 
Given that DNA damage is considered to be a major inhibitor of cell cycle 
progression, cytotoxic agents that induce DNA damage and subsequent cell cycle arrest, 
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have been a mainstay of treatment for multiple cancer types. Doxorubicin, a 
Topoisomerase inhibitor, and cisplatin, a DNA cross linking agent, have shown 
therapeutic efficacy in multiple cancer types and are two of the most commonly utilized 
chemotherapies in HCC. However, response rates are low and neither drug prolongs 
survival significantly in HCC patients (42). Furthermore, attempts to increase the drug 
concentration to levels at which there is an anti-tumor response also results in significant 
toxicities. Studies have demonstrated that transarterial chemoembolization using either 
doxorubicin or cisplatin can efficiently increase the dose of drug delivered to the tumor 
without causing significant toxicity to normal hepatocytes (43, 44). Capecitabine, a drug 
converted to 5-fluorouracil (5-FU), acts on DNA synthesis and can slow tumor growth. It 
is currently used as an adjuvant therapy post-surgical resection in HCC. Clinical trials 
showed lower recurrence rate, greater time to tumor recurrence and a near doubling in the 
5-year survival rate with adjuvant Capecitabine (45). Overall, although effective in vitro, 
treatment with cytotoxic agents in HCC is limited due to the toxicities associated with 
treatment. 
 
Microtubule Inhibitors 
Microtubule targeting agents disrupt microtubule dynamics and lead to prolonged 
cell cycle arrest followed by cell death. These drugs target the polymerization dynamics 
of microtubules which is required for spindle formation. The most commonly used 
microtubule targeting agents used clinically are either vinca-alkaloids or taxanes. Vinca-
alkaloid derived compounds destabilize spindle formation by preventing microtubule 
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assembly whereas taxanes stabilize spindle formation by preventing microtubule 
disassembly. These drugs are used to manage multiple malignancies including breast, 
lung, ovarian, prostate, leukemias and lymphomas.  
Despite the thorough investigation of vinca-alkaloids in other malignancies, there 
are limited trials for the use of such agents in HCC (46). A phase 2 study of Vindesine in 
16 HCC patients who did not qualify for transplantation did not show any therapeutic 
effect as median progression-free survival was 3.4 months (47). Contrarily, taxanes, such 
as docetaxel (48) and paclitaxel (49), exerted an anti-tumor effect in vitro. However, 
these in vitro results did not translate to a durable anti-tumor response in phase 2 trials 
(50).  
A major limitation to the use of microtubule inhibitors is due to the fact that they 
also exert their effects on normal dividing cells. Consequently, patients treated with these 
drugs often experience severe neurotoxicities that effect movement and sensation. 
Moreover, these patients may also experience severe myelosuppression (51). Such 
toxicities limit the use of microtubule inhibitors in cancers.  
 
Pan-CDK Inhibitors  
Cyclin inhibitors are also attractive targets in cancer therapeutics as inhibition of 
cyclins and treatment with anti-CDK agents can induce cell cycle arrest at G1/S and 
G2/M transitions. Flavopiridol was one of the first CDK inhibitors to enter the clinic. 
Flavopiridol is considered to be a pan-cyclin inhibitor as it inhibits CDKs 1, 2, 4 and 7. 
Although it showed a response rate of ~70% in hematological malignancies, flavopiridol 
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monotherapy failed to show considerable response in solid tumors (41). However, 
flavopiridol combined with doxorubicin resulted in stable disease in sarcoma patients 
(52) and flavopiridol in combination with paclitaxel and carboplatin resulted in stable 
disease in non-small cell lung cancer (53).  Yet when Phase 2 trials were conducted in 
HCC patients, flavopiridol either as monotherapy or when combined with other cytotoxic 
agents yielded no durable anti-tumor response (54). In general, the first generation CDK 
inhibitors such as flavopiridol were unable to exhibit an antitumor response due to the 
fact that they exhibited a low therapeutic index and raising the dose resulted in toxicities. 
However, the success of these compounds in some tumor models prompted the 
discovery of second-generation inhibitors such as Dinaciclib. Dinaciclib, was found by 
screening individual compounds against an ovarian cancer mouse xenograft model. 
Dinaciclib was shown to be 16-fold more potent at inhibiting CDKs 1, 2, 5 and 9 and 
100-fold more potent at inhibiting Rb phosphorylation than Flavopiridol (55). Dinaciclib 
showed efficacy in Phase 1 clinical trials in hematological malignancies such as multiple 
myeloma (56) and chronic lymphocytic leukemia (57), however, like its predecessor it 
failed to show efficacy as monotherapy in solid tumors such as HER2-negative metastatic 
breast cancer (58) and NSCLC (59).  
A phase 1 study in 2013 assessing safety of Dinaciclib across solid tumor types, 
showed no anti-tumor activity in the one patient with HCC (60). Hence, more thorough 
examination of Dinaciclib in HCC was not warranted at the time. However, recent studies 
revealed that Dinaciclib susceptibility was dependent on MYC 
overexpression/amplification in Triple Negative Breast Cancers(61), B-Cell Lymphomas 
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(62), and HCC (63). In light of this new data, perhaps new clinical trials studying 
Dinaciclib is warranted in which patients are stratified by MYC expression.  
 
CDK4/6 Inhibitors 
The development of pan-CDK inhibitors prompted the discovery of CDK 
selective inhibitors in order to reduce toxicities associated with pan-CDK inhibition. The 
CDK4/6 inhibitors Palbociclib and Ribociclib showed potent and durable anti-tumor 
responses in genetic mouse models and pre-clinical studies for both hematological 
malignancies (64-66) and solid tumors (67). Surprisingly, Palbociclib showed efficacy in 
Glioblastoma Multiforme (GBM) models as it was able to cross the blood-brain barrier 
when delivered systemically (68). Palbociclib induced cell cycle arrest in HCC cell lines, 
in organotypic ex vivo cultures from HCC patients and in HCC mouse models (69). Not 
surprisingly, HCC tumors with RB deletion and cyclin E amplification were resistant to 
palbociclib and CDK4/6 inhibitors (69, 70). In addition, tumors that had elevated levels 
of CDK4/6 activity were found to be more resistant to therapy (67). Interestingly, normal 
cells displayed low toxicity to CDK4/6 inhibitors in pre-clinical models. One possible 
explanation for this was that normal cells can rely on CDK2 activity in order to progress 
through the cell cycle after CDK4/6 inhibition (67). Currently, Palbociclib has been 
approved by the FDA for the treatment of HER2-positive advanced breast cancer and is 
currently in being tested in phase 2/3 trials for NSCLC, GBM, Melanoma and HCC (71).  
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AURKA/B Inhibitors 
AURKA and AURKB represent a family of kinases which can regulate 
progression from S phase to G2, cytokinesis and chromosome segregation during mitosis. 
Treatment of cancer cells with Alisertib, a small molecular inhibitor for AURKA, 
induced mitotic arrest and polyploidy leading to cell cycle arrest in multiple myeloma 
(72), apoptosis in mantel cell lymphoma (73), and tumor regression in MYCN driven 
mouse models of neuroblastoma (74). Further studies in an HCC model driven by MYC 
overexpression and P53 loss, demonstrated that Alisertib resulted in MYC degradation 
and prolonged survival in this mouse model (75). Small molecule inhibition of AURKB 
via AZD1152 similarly showed therapeutic benefit as treatment induced apoptosis in 
HCC cell lines in vitro and in orthotopic hepatic xenografts in p53-wildtype, mutant and 
null cells (76).  
Phase 1 studies have been conducted in hematological malignancies (77) and 
solid tumors (78) using Alisertib and, like previous cell cycle inhibitors, Alisertib exhibits 
a greater anti-tumor response in hematological malignancies compared to solid tumors. 
One potential explanation for this trend is that hematological malignancies proliferate 
faster than solid tumors resulting in more frequent opportunities for the drug to have its 
effect (41). A phase 2 study with Alisertib showed a 21% response rate in patients with 
small cell lung cancer and an 18% response rate in breast cancer (72). Alisertib is 
currently in phase 2 trials for HCC. While AURKB inhibitors showed promise in pre-
clinical models, AURKB inhibitors have not shown significant improvements in survival 
in phase 2 trials (33).  
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Due to the structural similarities between different kinase families, many 
AURKA/B inhibitors also inhibit other tyrosine kinases related to angiogenesis and 
oncogenesis such as VEGFR2 and BCR-Abl (41). ENMD-2076 is one such AURKA 
inhibitor that also inhibits VEGFR2. This dual action mechanism allows for a sustained 
anti-proliferative effect with IC50s ranging from 25nM-700nM in breast, colon, 
melanoma, leukemia and multiple myeloma tumor xenograft models (79).  ENMD-2076 
showed extremely promising results in a phase 1 study in patients with HCC (80) and 
was subsequently granted orphan drug designation for HCC by the FDA.  
 Overall, the discovery of targeted therapies that inhibit mitosis and cell cycle 
progression have demonstrated significant benefit in multiple tumor type as these 
molecules have low therapeutic indices and limited toxicities on normal cells. 
Furthermore, targeting this vulnerability in HCC cells has been shown to be more 
efficacious than standard chemotherapy. Currently, small molecule inhibitors that target 
cell cycle progression and mitosis is an exciting frontier in HCC, however, the success of 
these compounds remains to be seen in future phase 2 clinical trials.   
 
CRISPR as a Tool for Discovery of Novel Therapeutic Targets 
Genetic screens enable identification and functional characterization of genes 
associated with a particular phenotype. Traditionally, genetic screens in cancer cells 
relied on random DNA mutagenesis induced via DNA damage or retrovirus mediated 
transposon integration (81). Sleeping beauty-based transposon screens succesfuly 
identified therapeutic targets and oncogenic drivers in multiple malignancies. These 
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targets include HDAC7 in hematopoietic malignancies (82), APC, PTEN and SMAD4 in 
colorectal cancers (83), the PI3K-AKT-mTOR pathway in osteosarcomas (84) and the 
HIPPO pathway in HCC (85). Although these approaches contributed to a greater 
understanding of tumor biology, identifying the genetic changes that were associated with 
a particular phenotype was challenging (81). With the discovery of RNAi, shRNA and 
siRNA-based screens allowed for loss of function screens in which the genetic 
perturbation could be easily detected as shRNAs used molecular tags. Although these 
screens furthered our understanding of tumor biology and revealed novel therapeutic 
targets, RNAi based screens were limited by a high number of false negatives due to low 
knockdown efficiency and the off-target effects of the particular sh/siRNA used (86).   
 
CRISPR Function 
The discovery of the CRISPR-Cas9 system and advances in modifying it for the 
genome engineering in mammalian systems allowed for another facile system that could 
probe gene function and be utilized in genetic screens. Briefly, the Cas9 enzyme homes 
in on a particular site in the genome using a single 20-nucleotide guide RNA (sgRNA) 
(87). It subsequently binds DNA and induces a double stranded break (DSB) upstream of 
a Protospacer Adjacent Motif (PAM) sequence, a short sequence of 2-6 nucleotides that 
varies depending on the bacterial origin of the Cas9 enzyme (87). The DSBs are repaired 
by two intracellular repair mechanisms: Non-homologous End Joining (NHEJ) or 
Homology-directed Repair (HDR). The NHEJ repair pathway is error prone and can 
introduce small insertions or deletions (indels) that can introduce frameshift mutations 
 19 
(88). These mutations result in gene silencing owing to the production of truncated 
polypeptide, and also often nonsense mediated decay of the transcript (88). Conversely, 
HDR precisely repairs the DSB using a homologous DNA template (89). Of note, NHEJ-
based repair occurs more frequently than HDR (89). The programmable and facile nature 
of Cas9 allows for forward genetic screens to be performed in various models. 
High-throughput CRISPR-based screens are performed by infecting cells with 
lentivirus consisting of a sgRNA library (90, 91). Briefly, CRISPR libraries typically 
contain multiple sgRNAs that target each gene. sgRNA oligos are pooled together and 
then cloned into an appropriate vector to create a pooled library. Cells are then 
transduced at a low multiplicity of infection (MOI) in order to achieving genomic 
integration rates of one sgRNA per cell (91). Cells can then be subsequently treated with 
a drug/toxin to produce a phenotype. Alternatively, cells can be passaged long term to 
identify genes that are required for cell growth. After a phenotype is produced, enriched 
or depleted sgRNAs are then identified via next generation sequencing.   
 
CRISPR Screens 
The first CRISPR based screens were published less than five years ago and 
identified genes that mediated resistance to the RAF inhibitor, vemurafenib (92), and 
nucleotide analog, 6-thioguanin (93). Since then CRISPR screening has gained increased 
popularity as a tool for genetic screens. A search for “CRISPR screening” in PUBMED 
reveals >600 papers all within the last 5 years. Although numerous CRISPR genetic 
knockout screens have been reported, it is important to mention that there are screens 
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utilizing other functions of CRISPR such as base-editing and transcriptional activation 
using CRISPRa (94-96). Furthermore, conjugating a catalytically inactive Cas9 (dCas9) 
with transcriptional repressors, such as KRAB, and activators, such as p300, has allowed 
for identification of regulatory elements at particular genomic loci (97). Finally, CRISPR 
screens have also been utilize to identify essential non-coding RNAs (98).  
Numerous studies have conducted genetic knockout screens using the 
CRISPR/Cas9 system. These screens have identified genes essential for fitness in human 
cells (99), genes essential for proliferation of human cancer cell lines and mouse models 
of cancer (100). Notably, DEPMAP is a recently created publicly available dataset which 
compiled data from CRISPR screens that were conducted in over 200 human cancer cell 
lines (101, 102). Of note, CRISPR screens are now beginning to be conducted in vivo. 
The major limitation to in vivo CRISPR screens is efficient delivery of the library to 
target cells while maintaining a low MOI and an even representation of sgRNAs. To 
overcome this barrier, groups have begun transducing cells in vitro and injecting the cells 
in vivo (103-105).  
 
CRISPR vs RNAi Screens 
CRISPR based screens initially gained traction due to the easy programmable 
nature of the nuclease and the fact that CRISPR often resulted in greater and more stable 
knockdown of targets compared to traditional RNAi (106). In line with this, some of the 
first CRISPR screens were able to identify a greater number of essential genes compared 
to RNAi screening (99) and exhibited reduced off target effects compared to RNAi 
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screening (107). Two years after the first CRISPR screen was published numerous 
studies were published that presented side by side comparisons of CRISPR and RNAi 
based screens (108, 109).   
 In the study by Munoz et al., the authors constructed complementary shRNA and 
sgRNA libraries and screening five cancer cell lines (three of which were diploid and two 
of which were aneuploid). They found that the sgRNA screen identified 2-5 times more 
essential genes than the shRNA screen. When analyzing false positive hits, the authors 
found that there were no false positive hits in the three diploid cell lines but the sgRNA 
screen did produce false positives in the two aneuploid cell lines. Moreover, the false 
positive hits mapped to regions of genomic amplifications (108). In a similar study 
conducted by Aguirre et al., the authors similarly found that CRISPR screens yielded 
more hits than traditional RNAi screens. However, they unexpectedly found that sgRNAs 
that target regions within genomic amplifications had a greater decrease in cell 
proliferation/survival than sgRNAs that targeted genes outside of the amplified regions 
(109). A later study demonstrated that CRISPR editing activated the DNA damage 
response resulting in P53 activation and cell death (110). Therefore, the decreased 
survival of editing in regions of genomic amplifications can be attributed to activation of 
DNA damage. Taken together the results of the studies by Munoz et al. and Aguirre et al. 
provided evidence towards the superiority of CRISPR screening in providing targets but 
cautioned the interpretation of these results in cell lines that harbored copy number/ploidy 
variations.  
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Furthermore, other studies have cautioned against the use of CRISPR screening in 
cell lines that the contain an intact p53 pathway (110), mutations in DNA repair 
pathways, and editing genomic loci marked with heterochromatin or non-accessible DNA 
(111) as all these factors can reduce the editing efficiency in cell lines. RNAi methods 
were demonstrated to be more amenable for synthetic lethal screens since the machinery 
required for knockdown was cytoplasmic and did not depend on locus accessibility, 
chromatin conformation or ploidy (112). 
 
Genetic Screening in Hepatocellular Carcinomas 
The utility of CRISPR screens allows for discovery of novel therapeutic targets, 
this is particularly important for diseases such as HCC which have limited therapeutic 
targets. Unbiased screening for drug targets in HCC via transposon, RNAi and CRISPR 
have revealed novel targets in HCC. Transposon based screening allowing for insertional 
mutagenesis identified Ubiquitin Conjugating Enzyme E2 H (UBE2H) and a truncated 
EGFR variant as drivers of HCC tumorigenesis (111).  RNAi based screening identified 
HCC implicated exportin (XPO4) and 13 other genes as tumor suppressors in HCC (113), 
and also identified Mapk14 (p38a) as a mediator of sorafenib resistance in a mouse model 
of HCC (114). More recently a genome wide RNAi screen identified Mitochondrial-
Processing Peptidase Subunit Beta (PMPCB) as a therapeutic vulnerability in HCC as 
knockdown inhibited proliferation and also decreased expression of stem cell genes that 
are associated with the S2 HCC subclass (115). An ex vivo CRISPR screen conducted in 
our lab reported NF1 as a novel tumor suppressor gene in HCC (104). Furthermore, 
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another group conducting a CRISPR kinome screen in HCC cells identified CDK7 as a 
therapeutic target in MYC driven HCCs (116). In this thesis, I utilize a CRISPR kinome 
screen to identify Transformation/Transcription Domain Associated Protein (TRRAP) as 
a therapeutic target in HCC.  
TRRAP 
TRRAP is a large (3828 amino acids) multidomain protein of the 
phosphoinositide 3-kinase-related kinases (PIKK) family. TRRAP was first identified as 
an interacting partner of c-MYC and E2F1 and is required for the transformation ability 
of c-MYC (117). TRRAP is highly conserved in evolution and has homologs found in 
many model systems utilized today (Table 1.1). Analysis of TRRAP sequences across 
species revealed multiple conserved domains: a nuclear localization domain, two 
tetratricopeptide repeat (TPR) motifs, multiple Huntingtin, elongation factor 3, PR65/A, 
and TOR (HEAT) domains, a FATC domain, a Leucine zipper and a PIK-like domain.  
Firstly, TRRAP contains a functional nuclear localization domain (118). Next, 
TRRAP contains two TPR domain, which each encode two anti-parallel α helices 
separated by a turn (119), and a number of HEAT domains. Mutagenesis of these 
domains in Tra1, the Saccharomyces cerevisiae homolog of TRRAP, demonstrated that 
these domains aid in the assembly of the two TRRAP containing multi-subunit 
complexes (120). Furthermore, mutations within these domains reduced viability (120). 
Additional studies demonstrated that the HEAT domains were required for interaction 
with c-MYC (121) and p53 (122). TRRAP also contains a leucine zipper that promotes 
TRRAP-DNA interactions (118). The FATC domain is important for binding with the 
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histone acetyltransferases KAT5 and ATM signaling (123). Finally, like all PIKK family 
members, TRRAP contains a PIK-like domain. This domain is a highly conserved across 
evolution and resembles the catalytic domain of PI3kinases. However, sequence analysis 
of this domain revealed that it lacked the conserved amino acids required for phosphate 
transfer activity. Therefore, TRRAP is a pseudokinase which largely functions as a 
scaffold protein (99).  Interestingly, a recent study in S. cerevisiae demonstrated that 
deletion of the pseudokinase domain of Tra1 disrupted nuclear localization presumably 
though decreased binding of TRRAP to its two Histone Acetyltransferase (HAT) 
complexes (124). Furthermore, this domain was also required for Myc mediated 
transformation (121).  
Given that TRRAP contains multiple HEAT and other protein binding domains, it 
was important to identify which proteins TRRAP interacted with. Upon its discovery, 
TRRAP was demonstrated to interact with c-MYC. Subsequent studies demonstrated that 
TRRAP also interacted with other factors involved in the DNA damage response 
including p53, E1a, PPAR, LXR, FXR, -catenin and BRCA1 (118). TRRAP was also 
found to regulate ras signaling and drive cell fate decisions in Caenorhabditis elegans 
(106). This diverse range of binding partners suggested that TRRAP controls multiple 
cellular processes.  
 
TRRAP Functions 
Genetic studies have begun to elucidate the role biological role of TRRAP. Early 
studies demonstrated that loss of Tra1 in yeast resulted in decreased cell viability (125) 
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whereas loss of TRRAP in mice resulted in embryonic lethality as embryos did not 
survive past the blastocyst stage (126). Similarly, loss of function mutations in Trr-1 in 
C. elegans resulted in developmental defects, specifically vulval cell fates (127) and 
mutations in Nipped-A, the Drosophila melanogaster (D. melanogaster) homolog, 
resulted in defects in wing development (128). Taken together the studies suggest 
TRRAP plays an integral role in development.  
In order to further investigate the functions of TRRAP during embryogenesis, 
inducible TRRAP loss models were generated. Depletion of TRRAP in Mouse 
Embryonic Fibroblasts (MEFs) resulted in loss of clonogenicity and mitotic arrest (129). 
Analysis of differentially expressed genes in TRRAP depleted cells revealed that TRRAP 
regulated expression of genes responsible for cell cycle progression, cell adhesion, 
protein synthesis, metabolism and signal transduction via changes in histone H3 and  H4 
acetylation (130). Later studies demonstrated that TRRAP loss in mouse ES cells resulted 
in premature differentiation associated with loss of chromatin acetylation and subsequent 
heterochromatin formation resulting in decreased expression of stemness master genes 
Oct4, Sox2 and Nanog (131).   
Tissue specific analysis of TRRAP loss in vivo demonstrated an integral role for 
TRRAP in cell cycle progression. TRRAP depleted hepatocytes were unable to 
regenerate after CCl4 induced damage due to failure to induce expression of cyclin A 
(132). Depletion of TRRAP in the central nervous system resulted in impaired 
differentiation of neuronal progenitor cells due to failure to induce timely expression of 
E2F related cell cycle targets (133).        
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TRRAP-HAT Complexes 
Mass spectroscopy, cross linking and FRET studies revealed that TRRAP was a 
component in two major HAT complexes: the SAGA complex containing KAT2A (also 
known as GCN5) and the H2A/H4 HAT complex centered around p400 and KAT5 (also 
known as TIP60) (134-136). TRRAP was also shown to form a third complex with p400 
and BAF53. This complex also had HAT activity, but it was independent of KAT5 (137). 
Later studies demonstrated that each TRRAP containing complex had distinct functions 
granted to the complex by the HAT effectors KAT2A and KAT5.   
 The TRRAP-KAT2A complex also plays major roles in development. Loss of 
KAT2A alone is embryonic lethal. However, interestingly, deletion of individual 
components of the of the TRRAP-KAT2A complex has different effects—deletion of 
KAT2A resulted in embryonic lethality after the blastocyst stage (embryonic day 10.5) 
(138) whereas deletion of PCAF was compatible with full development (139). This 
suggested that components within this complex had some overlapping functions.   
The TRRAP-KAT2A complex can regulate expression of genes via histone 
acetylation preferentially on histone H2B residues K11 and K16 and histone H3 residues 
K9 and K14 (140). CHIP analysis of the KAT2A complex revealed that it was 
responsible for regulating expression of genes involved in telomere maintenance and 
mRNA export (141, 142). The KAT2A complex can also acetylate non-histone substrates 
such as Nf-B, c-Myc and Cyclin A (143). KAT2A has also been implicated in 
transformation as the HAT activity of KAT2A was required for c-MYC mediated 
 27 
transformation (144). Moreover, KAT2A has also been implicated in acetylating Pygo2, a 
component of the WNT signaling pathway (145).  
Like KAT2A, KAT5 also plays a major role in development as disruption of 
p400/KAT5 complex results in impaired ESC differentiation (146). However, the 
TRRAP-KAT5 complex plays a distinct role from the KAT2A complex in that it detects 
and aids in the resolution of DNA damage. After a double strand DNA break (DSB), the 
TRRAP-KAT5 complex is recruited to the break site along with ATM. ATM 
phosphorylates the histone H2A.X to form γH2A.X to recruit other DNA repair proteins 
to repair the break. Meanwhile, KAT5 acetylates histone tails to facilitate chromatin 
relaxation around the break site (147). As mentioned earlier, the TRRAP-KAT5 complex 
is also responsible for regulating gene expression by acetylating residues H2AK5, H3K14 
and H4K5/8/12/16 (140). Similar to KAT2A, KAT5 has also been implicated in 
acetylation and activation of non-histone substrates including MYC, ATM, E2F1 and p53 
in order to regulate cell fate decisions (148).  
 
Senescence 
Observations of serially passaging primary cells in culture by Leonard Hayflick 
revealed that cells have a finite replicative capacity after which they have limited 
proliferative capacity (149). Hayflick later proposed that this arrest was due to “aging or 
senescence at a cellular level” (150). Cellular senescence is a stable, essentially 
irreversible, state of cell arrest that can occur during the normal aging process but can 
also occur in response to a number of toxic stressors such as growth factor withdrawal, 
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DNA damage, oncogene activation, tumor suppressor inactivation and oxidative stress 
(151). Consequently, there are a number of markers that are both specific and unique to 
senescence.  
Senescent cells display a number of characteristics that allows for their detection. 
Morphologically, senescence cells have a large flattened morphology which resembles a 
sunny-side up egg when observed under a light microscope. In addition to the unique 
morphology, Senescence Associated β-Galactosidase (SA-β-Gal) is a commonly used 
biomarker for senescent cells (152). SA-β-Gal staining takes advantage of the fact that 
senescent cells have increased lysosomal β-galactosidase activity due to expansion of the 
lysosomal compartment. Lysosomal β-galactosidase is encoded by the GLB1 gene, 
however, interestingly, GLB1 plays no role in the senescence response as cells depleted 
of GLB1 still undergo senescence (153). A critical ingredient in the SA-β-Gal staining 
solution is X-gal. When cleaved by β-galactosidase, X-gal produces a blue precipitate 
that is detectable via light microscopy (152). The specificity of detecting lysosomal β-Gal 
in senescent cells compared to normal cells occurs via pH. Lysosomal β-Gal is typically 
detected at pH 4, however since senescent cells have an expanded lysosomal 
compartment, β-Gal in senescent cells can be detected at pH 6 (154).   
Additional molecular markers of senescence take advantage of the fact that these 
cells are arrested during the cell cycle. Senescent cells exhibit increased expression of the 
Cyclin Dependent Kinase Inhibitors (CDKI) p15INK4B, p16INK4A, and p21CIP1. Increased 
expression of these CDKIs will result in hypo-phosphorylation of Rb (151).  
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Changes in global chromatin structure are also associated with senescence. 
Senescence associated heterochromatin formation (SAHF) are readily detectable in 
senescent cells as distinct DAPI-dense foci mediated by deposition of H3K9me3 
marks(155). Furthermore, in order to mediate some of the nuclear changes associated 
with senescence, senescent cells also have reduced expression of Lamin B1 (156). 
However, the role of Lamin B1 reduction in senescence remains unclear. Finally, 
senescence is also accompanied with secretion of pro-inflammatory cytokines such as 
IL1, IL6 and IL8. This phenomenon is known as the Senescence Associated Secretory 
Phenotype (SASP). Overall, senescence can be induced by a wide variety of insults to the 
cell. Depending on the mechanism of induction, senescent cells will exhibit additional 
markers that are unique to that mechanism.  
 
Replicative Senescence 
Hayflick’s original observation, now termed the cell’s Hayflick limit, was found 
to be due to telomere attrition (157). Functional telomeres prevent DNA repair 
machineries from recognizing chromosome ends as DNA DSBs. When telomeres reach a 
critical length, their protective function during DNA replication is compromised and a 
DNA damage pathway mediated by ATM and ATR is activated (158). ATM and ATR 
signaling converge on p53 and result in hypophosphorylation of Rb and senescence. In 
line with telomere regulation, additional studies have demonstrated that cells deficient in 
the enzyme telomerase (TERT), which is responsible for telomere repair, undergo 
senescence (159). Interestingly, expression of TERT was unable to reverse replicative 
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senescence but silencing of p53 and p16 allowed a subset of cells to re-enter the cell 
cycle (160).   
The functional role of senescence was debated for many years after Hayflick’s 
discovery as some suggested that senescence was a barrier to tumorigenesis whereas 
others suggested that senescence was merely a state of “cellular exhaustion.” However 
work by Manuel Serrano in Scott Lowe’s lab later revealed the role of senescence in 
tumorigenesis (described below)  
 
Oncogene Induce Senescence (OIS)  
After the discovery of the Ras oncogene, Weinberg and colleagues began to test 
its tumorigenic potential. Weinberg was able to demonstrate that DNA isolated from 
carcinomas driven by RAS mutations could transform immortalized cell lines (161), 
however, oncogenic RAS alone was insufficient to transform primary cell lines (162). 
Work by Manuel Serrano later demonstrated that overexpression of oncogenic RAS in 
primary cells dramatically reduced cell growth and induced senescence via activation of 
p53, increased expression of the CDKIs p21, p15 and p16, and hypophosphorylation of 
Rb. The cells were arrested during G1 and stained positive with SA-β-Gal. To further 
support Weinberg’s initial findings, he demonstrated that immortalizing the cell line with 
E1A reduced the cell cycle arrest induced by oncogenic Ras (163). Later studies 
demonstrated that the DNA damage response also reinforced the senescence program 
triggered by oncogenic RAS(164).  Interestingly, overexpression of TERT to “near-
immortalization” levels did not rescue senescence suggesting that OIS was distinct from 
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replicative senescence (165). Serrano concluded that senescence was a tumor-suppressive 
mechanism and served as a barrier to transformation.  
Additional evidence that distinguishes OIS is seen in melanoma literature. A large 
portion of melanomas are driven by the oncogenic mutant of BRAF V600E (166). 
Melanocytic nevi, more commonly known as moles, are benign tumors that have low 
propensity to develop into melanomas. However, a large portion of nevi contain the same 
BRAFV600E mutation (167). In vitro and in vivo studies in mice demonstrated that these 
nevi expressed elevated levels of p16INK4A and stained positive with SA-β-GAL (168).  
Furthermore, it was found that there was no difference in telomere length between nevi 
and normal skin fibroblasts (169).  
Bypass of OIS generally involved the activation of an oncogene or inactivation of 
a tumor suppressor gene. In line with this, genetic screens have identified several 
oncogenes that can mediate bypass from OIS. Studies demonstrated that expression of 
DRIL1, TBX2, BCL6, and KLF4 can bypass OIS (170). Furthermore CXCR2-binding 
chemokines by senescent cells can reinforce senescence via activation of P53 (171). 
Furthermore, recent studies have demonstrated that OIS cells can indeed “escape” their 
senescent state (172). Implications of this escape, along with the mechanisms implicated 
in this process will be discussed in a later section.   
 
Chromatin Reorganization During Senescence 
Work by Masashi Narita demonstrated that OIS was accompanied by global 
changes in chromatin structure—specifically there was global induction of 
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heterochromatin formation mediated by Rb and p16 (155). These heterochromatin foci 
were detectable by intense DAPI staining. Moreover, the DAPI foci stained positive for 
repressive epigenetic marks such as H3K9me3, HP1, macroH2A and loss of the linker 
histone H1 (173, 174). While overexpression of H3K9 methylation “erasers” such as 
LSD1 and JMJD2C eventually led to reduced levels of the H3K9me3, deletion of 
SUV39H1, a H3K9 methylation “marker,” could reverse OIS (175). SAHF formation was 
also characterized by accumulation of HMGA proteins on heterochromatin (176). 
Interestingly, SAHF formation is predominantly seen in OIS as opposed to DNA damage 
induced senescence and replicative senescence (177). Furthermore, after transformation 
occurs via inactivation of p53 or ATM depletion, SAHF-like structures are retained 
(177). This is in line with the observation that cancers typically have higher levels of 
heterochromatin compared to normal tissue (178).  
It was initially thought that SAHFs function to repress expression of cell cycle 
genes in order to maintain cell cycle arrest (176), however, Fabrizzo d'Adda di Fagagna’s 
group also demonstrated that the SAHF hampered the DNA damage response mechanism 
suggesting that SAHF does not simply function as a mechanism to regulate gene 
expression (177).  
 
Senescence Associated Secretory Phenotype (SASP) 
 SASP was first described as a milieu of pro-inflammatory cytokines secreted after 
senescence induced by DNA damage, replicative exhaustion and oncogenic RAS by 
Judith Campisi’s group (179). All three pathways share similarity in that senescence is 
 33 
mediated through the DNA damage response, suggesting that the DNA damage response 
was required for SASP activation. In line with this, they demonstrated that neither p53 
nor p16 was required for the initiation and maintenance of the SASP  (179). Furthermore, 
additional studies demonstrated that ectopic expression of p21 and p16 did induce 
senescence but without SASP induction (180).  
 The SASP program is thought to be largely activated by two transcription factors- 
NFκB and C/EBPβ (178). The major target genes implicated in the SASP are IL1, IL6 
and IL8. Once secreted, IL1, IL6 and IL8 have both autocrine and paracrine roles. The 
autocrine signaling effects reinforce NFκB and C/EBPβ activation and initiate a positive 
feedback loop for expression of SASP genes. The paracrine signaling has two major 
effects. First, the SASP-excreted-interleukins induce senescence in neighboring cells. 
Interestingly, this senescence was dependent on p21, p16 and p53. Second, the presence 
of these interleukins recruits immune cells in vivo to clear senescent cells (181). 
Clinically, this is relevant in that senescence induction can lead to immune mediated 
tumor clearance in patients. In line with this, Scott Lowe’s group was the first to show 
that senescence in HCC cells, induced via p53 restoration, resulted in tumor regression 
via Natural Killer (NK) cell mediated tumor clearance (182).  
However, studies are now demonstrating that although the SASP can promote 
tumor clearance, the SASP can also have a pro-inflammatory effect and can promote 
tumorigenesis in some models (183). Initial studies demonstrated that when tumor cells 
were injected with senescent fibroblasts into nude mice, tumor growth was accelerated 
compared to when tumor cells are injected with normal fibroblasts (184). The pro-
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tumorigenic effect of the SASP along with reversal of senescence will be further 
discussed in a later section.  
 
Thesis Preview 
The work described in this thesis will utilize a CRISPR screen to identify TRRAP 
as a therapeutic target in HCC. Loss of TRRAP and its cofactor, KAT5, results in 
decreased proliferation of HCC cells. I will identify a network of genes regulated by 
TRRAP and KAT5 that are responsible for mitotic progression in HCC and further 
identify TOP2A as TRRAP/KAT5 target gene. Furthermore, I will demonstrate that loss 
of TRRAP, KAT5, and TOP2A results in senescence of HCC cells during G2 that is 
independent of traditional mediators of senescence such as p53, p21, Rb, heterochromatin 
formation and DNA damage.   
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Organism TRRAP Homolog 
Mus Musculus Trrap (117) 
Saccharomyces cerevisiae Tra1 (134) 
Caenorhabditis elegans Trr-1 (127) 
Drosophila melanogaster Nipped-A (128) 
Arabidopsis thaliana TRRAP (117) 
 
Table 1.1 TRRAP homologs identified in other model systems 
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CHAPTER II 
CRISPR Screening identifies TRRAP as a therapeutic target in HCC 
 
Preface 
The screen conducted in this study was performed by two other members of the Xue Lab, 
Dr. Suet-Yan Kwan and Dr. Chun-Qing Song. 
  
Introduction 
Liver cancer accounts for more than 27,000 deaths in the United States and more 
than 700,000 deaths worldwide each year (17, 185). The 5-year survival rate for liver 
cancer patients is 18% and the major subtype of liver cancer is hepatocellular carcinoma 
(HCC) (6). Current approved advanced HCC treatments include multi-kinase inhibitors 
regorafenib, lenvatinib and sorafenib, which extend patient survival by several months 
only, and the immune checkpoint inhibitors Nivolumab and Pembrolizumab, which show 
~20% response rates as a second line of therapy (6). The clinical need for more effective 
HCC treatments remains unmet partially because HCC is genetically heterogeneous and 
because HCC driver genes amenable to targeted therapy are largely unknown(17, 186). 
Identifying genes whose depletion can inhibit HCC growth, and determining the 
mechanisms involved, will aid the development of targeted therapies for HCC patients.  
Using a kinome CRISPR screen in three HCC cell lines, we identified 
transformation/ transcription domain-associated protein (TRRAP) as the top-ranking 
candidate gene required for HCC cell growth. TRRAP, a pseudokinase member of the 
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PI3 kinase-like family, acts as a scaffold protein in histone acetyltransferase (HAT) 
complexes (118, 187-189) that regulate transcription, DNA repair, and replication (118). 
TRRAP is also a key regulator of cell cycle progression and stemness in embryonic stem 
cells and cortical apical neural progenitors(131, 133). 
TRRAP is mutated and amplified in different cancer types, including melanomas, 
gastric, and uterine cancers (190-192), and has been implicated in oncogenic 
transformation. Indeed, the TRRAP S722F hotspot mutation in melanomas can transform 
NIH3T3 cells (190). Moreover, wildtype TRRAP is required for transformation by c-
myc/Hras and E1A/Hras in rat embryo fibroblasts (117) and MYC-dependent tumor 
initiation in a breast cancer model (193). By contrast, depletion of TRRAP can induce 
apoptosis and differentiation in lymphoma and brain-tumor initiating cells (194, 195). 
Given its role in diverse cellular processes, it is possible that TRRAP and its regulated 
pathways are altered in cancer. However, the extent of TRRAP alterations and its 
function in cancer cells, particularly in the context of HCC, is not established. 
 
Results 
CRISPR screen identifies potential therapeutic vulnerabilities for HCC 
To identify genes that are required for cell growth in HCC, we infected three 
HCC cell lines (Huh7, HepG2, and Hep3B) with a kinome CRISPR library that targets 
763 kinases with 8 single guide RNAs (sgRNAs) per gene. To determine changes in 
sgRNA representation, we harvested genomic DNA from cells of an early passage and 
after 10 passages, then amplified and identified sgRNAs using PCR and deep sequencing, 
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respectively. Of the 763 kinases challenged with sgRNA, we found that 31 genes were 
significantly depleted in all three HCC cell lines (Figure 2.1A, 1D). This result provides 
in-vitro support to the current theory in the field surrounding HCC therapeutics- few 
unique molecular targets exist for HCC due to its heterogeneity between patients. GO 
analysis of the 31 depleted genes revealed that the major pathways that were depleted 
revolved around P53 and cell cycle regulation (Figure 2.1A). Among these 31 genes, 8 
genes (AURKB, BUB1B, CDC7, DTYMK, PGK1, TPR, TRRAP, VRK1) were 
expressed at least 1.5-fold higher in HCC compared to non-tumor tissue (Figure 2.1B). 
High expression levels of these genes were associated with poor survival in HCC patients 
(Figure 2.1C). Of note, previous studies have shown that AURKB, DTYMK, PGK1, 
TPR, and VRK1 promote HCC tumorigenesis (196-200). 
Out of the 8 genes, TRRAP is the top depleted gene in all three cell lines (Figure 
2.1D). Using additional published patient data sets, we confirmed that TRRAP expression 
is higher in tumor compared to matched normal tissue (Figure 2.2A), and increased 
TRRAP expression is correlated with poor survival (Figure 2.2B). Analysis of the TCGA 
data set revealed that 12% of HCC patient samples have increased TRRAP mRNA 
expression, amplification and/or mutations in the TRRAP gene (Figure 2.2D). We also 
investigated whether TRRAP expression is correlated with certain gene signatures in 
HCC. We performed Ingenuity pathway analysis and found that TRRAP expression is 
positively correlated with expression of genes that are involved in ‘molecular 
mechanisms of cancer’, ‘role of BRCA1 in DNA damage response’ and growth factor 
 39 
signaling pathways (Figure 2.2E). These results suggest that TRRAP may have an 
oncogenic role in HCC. 
 
TRRAP and its co-factor KAT5 are required for cell growth in HCC 
To understand the function of TRRAP in HCC, we depleted TRRAP expression 
in Huh7, Hep3B and SNU-475 cells using CRISPR (sgTRRAP) (Figure 2.3A). Loss of 
TRRAP resulted in decreased cell growth and colony formation in these cell lines (Figure 
2.3B and 2.3C). For the subsequent mechanistic studies we utilized the HUH7 and SNU-
475 cell lines as these cells had the greatest and most consistent knockdown of TRRAP 
protein after lentiviral infection.  
TRRAP is an adaptor protein in several HAT complexes. In mammalian cells, 
TRRAP predominantly binds to KAT2A and KAT5(187-189). We found that TRRAP 
and KAT5 co-localized to the nucleus in Huh7 and SNU-475 cells (Figure 2.4A). We 
found that TRRAP depletion resulted in decreased KAT5 and KAT2A expression at the 
protein, but not mRNA level, in Huh7 and SNU-475 cells (Figure 2.4B and Figure 2.4C). 
Loss of KAT2A and KAT5 was more dramatic in Huh7 cells compared to SNU-475 cells 
as knockdown of TRRAP protein was greater in HUH7 cells after lentiviral infection 
with sgTRRAP (Figure 2.3A). To investigate whether KAT2A and KAT5 protein 
become unstable due to increased protein degradation in the absence of TRRAP, we 
inhibited proteasomal and lysosomal protein degradation in sgTRRAP cells with MG132 
and chloroquine respectively. However, we found that MG132 and chloroquine could not 
rescue KAT2A and KAT5 protein expression in sgTRRAP cells compared to the positive 
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control proteins utilized in this study (Figure 2.4D), suggesting a degradation-
independent mechanism.  
To determine whether TRRAP depletion reduces cell proliferation due to loss of 
KAT2A or KAT5 expression, we depleted KAT2A and KAT5 using CRISPR (sgKAT2A 
and sgKAT5) in Huh7 and SNU-475 cells (Figure 2.5A and Figure 2.5B). We found that 
depletion of KAT5, but not KAT2A, reduced cell growth and colony formation similarly 
to TRRAP-depleted cells (Figure 2.5C).  
To investigate whether depletion of TRRAP, KAT2A, and KAT5 affect tumor 
growth in vivo, we injected nude mice subcutaneously with Huh7 cells expressing 
sgTRRAP, sgKAT2A, or sgKAT5. TRRAP- and KAT5-depleted tumors were 
significantly smaller than tumors in non-targeting controls. However, KAT2A depletion 
did not have any effect on tumor size at the end point of the study (Figure 2.6A). To 
investigate the role of TRRAP in HCC tumor in initiation, we injected C57/BL6 mice 
with three plasmids which encoded for sgTrrap or sgNT, sgP53 and a sleeping beauty 
based Myc transposase system (Figure 2.6B) via hydrodynamic tail vein injection. 
Overexpression of Myc along with P53 loss in hepatocytes is a well-established murine 
model of HCC (104, 201). After four weeks there were no gross liver tumors in mice 
injected with sgTrrap whereas mice injected with sgNT developed multiple tumors in the 
liver. Furthermore, clusters of immune cells were present in liver sections injected with 
sgTrrap. These clusters were negative for the lymphocyte marker CD4 and positive for 
the macrophage marker F480 (Figure 2.6C).   
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Identification of genes repressed and activated by TRRAP in HCC and Glioblastoma 
The function of TRRAP in transcriptional regulation has been well described 
(118). To identify genes that are regulated by TRRAP to promote HCC cell growth, we 
performed RNA-sequencing in sgTRRAP Huh7 cells to identify differentially-expressed 
genes. Gene ontology (GO) analysis of genes that were down-regulated in sgTRRAP 
cells were enriched in cell cycle processes, including mitosis, chromosome segregation, 
and cell division (Figure 2.7A). Genes that were up-regulated in sgTRRAP cells were 
enriched in nucleic acid processing (Figure 2.7B).  
Next, we cross referenced our RNA-sequencing results with published data sets to 
identify candidate genes that are activated by TRRAP in HCC. We looked for genes that: 
firstly, were down-regulated in sgTRRAP cells from our RNA-sequencing data (fold 
change<0.5), secondly, were positively correlated with TRRAP expression in the TCGA 
HCC data set (Spearman’s correlation0.3), thirdly, were overexpressed in HCC 
compared to non-tumor tissue in the GSE14520 data set (fold change2), and finally 
predict poor survival in HCC patients when highly expressed (Figure 2.7C). We also 
performed this analysis in the opposite direction to identify genes that were repressed by 
TRRAP. Using these criteria, we identified 22 HCC-relevant genes that were activated 
(Table 2.1, Figure 2.8, Figure 2.9). Moreover, 19 of the 22 TRRAP-activated genes were 
involved in either ‘cell cycle’ or ‘mitotic cell cycle’ from the GO analysis (Figure 7D). 
Using our criteria we also identified 3 genes that were repressed by TRRAP (Table 2.2). 
The 3 TRRAP-repressed genes (BAAT, ITIH1 and RDH16) were liver specific (Figure 
2.10). A similar pipeline was utilized to identify SLC7A11 as a BAP1 target gene across 
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multiple human cancers (202). When the authors of this pervious studied performed their 
overlapping analyses, they identified one target gene, SLC7A11, whereas our analyses 
yielded 22 potential TRRAP target genes in HCC.  
We focused on TRRAP-activated genes for further analysis as they might be 
potential targets for inhibiting HCC growth. To assess whether TRRAP may regulate the 
same genes in another cancer type, we analyzed gene expression data from the TCGA 
glioblastoma multiforme (GBM) data set. TRRAP is required for restricting 
differentiation of brain tumor-initiating cells that were derived from human GBM 
samples (190). We found that 14 of the 22 genes activated by TRRAP in HCC were 
positively correlated with TRRAP expression in GBM (Spearman’s correlation0.3, 
(Table 2.3), suggesting that TRRAP regulates a similar set of genes in both cancer types.  
 
TRRAP and KAT5 activate transcription of mitotic genes in HCC 
Since TRRAP- and KAT5-depleted cells display a similar phenotype, we asked 
whether TRRAP target genes were also regulated by KAT5. We analyzed previously 
published ChIP-sequencing data in mouse embryonic stem cells for KAT5 binding sites 
(203) and found that KAT5 binds to the transcriptional start sites of 19/22 genes activated 
by TRRAP (Figure 2.11A and Figure 2.12). After validating our RNA-sequencing data 
by confirming the downregulation of 6 genes after TRRAP depletion using qRT-PCR 
(Figure 2.11B and Figure 2.11C), we investigated the effect of KAT5 and KAT2A 
depletion on the expression of TRRAP target genes. We found that mRNA expression of 
TRRAP-activated genes was downregulated in sgKAT5 cells, but not in sgKAT2A cells 
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(Figure 2.11B and Figure 2.11C). In summary, TRRAP and KAT5 are required for 
transcriptional activation of mitotic genes. In HCC, these genes are clinically relevant 
since they are overexpressed and confer poor survival to patients.  
 
TOP2A is a downstream target of TRRAP and KAT5 
Based on our RNA-sequencing and bioinformatic analyses, we hypothesized that 
TRRAP depletion induces senescence by down-regulating mitotic genes. To investigate 
this, we focused on a downstream target of TRRAP and KAT5—Topoisomerase II alpha 
(TOP2A) (Table 2.1). TOP2A is highly expressed at G2/M phase and a key regulator of 
DNA decatenation during mitosis (204). We found that TOP2A expression was positively 
correlated with TRRAP expression in HCC and GBM patient samples (Figure 2.13A and 
Figure 2.13C) suggesting that TRRAP regulation of TOP2A was conserved between 
HCC and GBM. Moreover, TOP2A was overexpressed in HCC compared to non-tumor 
tissue, and its increased expression was associated with poor survival in HCC patients 
(Figure 2.13B). We confirmed that TRRAP and KAT5 depletion reduced TOP2A at the 
mRNA and protein level (Figures 2.11B, 2.11C, 2.13D).  
Analysis of published ChIP-sequencing data (203) revealed KAT5 binding to the 
transcriptional start site of TOP2A (Figure 2.11A). Using the ChIP-sequencing data, we 
predicted the KAT5 binding site in the human TOP2A promoter. We cloned a 500 bp (-
133/+367) region spanning the transcriptional start site of TOP2A to a luciferase 
promoter reporter and found that overexpression of TRRAP and KAT5 induced TOP2A 
promoter activity (Figure 2.14A). Previous studies have reported that TRRAP can bind 
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DNA directly independent of its HATs (118). However, we observed that KAT5 
overexpression alone was sufficient to drive promoter activity suggesting that TRRAP 
alone cannot bind the TOP2A promoter. Instead it is KAT5 mediated binding at the 
TOP2A promoter which drives transcription of TOP2A. Next, we depleted TOP2A with 
CRISPR (sgTOP2A) and found the reduced colony formation (Figures 2.14B and 2.14C), 
resembling those of TRRAP or KAT5 depletion. Together, our results suggest that 
TOP2A is a key mitotic target of TRRAP and KAT5 in regulating HCC cell growth. 
 
Discussion 
Here, we demonstrate that TRRAP functions in HCC cell proliferation by 
promoting mitotic progression. Previous studies in other cell types have identified several 
cell cycle genes that are regulated by TRRAP, including cyclins A2, D1, D2 and E, 
Mad1, Mad2, and MKI67 (126, 129, 132, 194). We found that the majority of TRRAP-
activated genes in HCC are involved in mitosis, and include genes not previously known 
to be TRRAP targets. Transcriptional activation of TRRAP-activated genes also required 
KAT5, indicating a specificity in recruitment of chromatin factors by TRRAP. Other 
TRRAP-interacting transcription factors, such as Myc and β-catenin, are frequently 
altered in HCC (14, 118). Investigations into whether these factors are important for 
TRRAP-dependent cell cycle control in HCC are warranted.   
The oncogenic roles of mitosis genes in tumorigenesis have been reported. Over-
expression of genes that regulate DNA replication and chromosomal segregation are 
involved in promoting chromosomal instability, a phenotype of aggressive cancers (205). 
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In HCC, YAP and FOXM1 promote chromosomal instability, and predict poor prognosis 
in patients (206). Of note, our study has identified FOXM1 is one of the TRRAP-
activated genes. We also found that 11 of our 22 TRRAP-activated genes overlapped 
with the chromosomal instability gene signature (205). Thus, TRRAP overexpression 
may contribute to chromosomal instability in HCC.  
Lineage tracing studies in both toxin-induced and genetic mouse models of HCC 
revealed that the cell of origin for HCC was hepatocytes (207). As cells transform from 
hepatocytes into HCC, normal hepatocytic functions are repressed—CYP450 levels and 
activities are suppressed (208), bile acid homeostasis is disrupted (209) and fatty acid 
metabolism is dysregulated (210). Interestingly our RNA-seq analysis identified Bile 
Acid-CoA:Amino Acid N-Acyltransferase (BAAT), Inter-Alpha-Trypsin Inhibitor Heavy 
Chain 1 (ITIH1), and Retinol Dehydrogenase 16 (RDH16) as genes that are repressed by 
TRRAP expression in HCCs.  
BAAT is responsible for the final step in bile acid synthesis (211) and also 
shuttles unconjugated bile salts through the peroxisome as it enters the enterohepatic 
circulation (212). Studies regarding BAAT and tumorigenesis are limited. One 
sequencing based study comparing the transcriptome in Intrahepatic cholangiocarcinoma 
(ICC) to normal tissue identified that BAAT levels were significantly decreased in ICC 
tissues (213). Furthermore another study demonstrated that bile acid synthesis is 
downregulated in HCC due to decreased expression of enzymes responsible for bile acid 
synthesis secondary to RAS/ERK activation (214). Yet, no studies have implicated the 
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role of BAAT in HCC tumorigenesis. Furthermore, studies have not implicated TRRAP 
in regulating bile acid synthesis.   
One of the major functions of the liver is the storage and metabolization of the 
soluble vitamins: Vitamin A, D, E and K. RDH16 is an enzyme responsible for the first 
step of synthesis of all-trans-retinoic acid (ATRA) from Vitamin A. ATRA has been 
demonstrated to have anti-tumor properties in HCC and cotreatment with sorafenib can 
result in synergy (215). Furthermore, RDH16 expression is decreased in alcohol induced 
HCC (216). However the function of RDH16 has not been studied in HCC. Studies in 
gliomas revealed that RDH16 could regulate differentiation as overexpression inhibited 
the expression of the stem cell markers Nestin, Oct4 and Sox2 and induced the 
differentiation of oligodendrocyte cells into stem-like gliomas (217). This suggests that 
TRRAP regulation of RDH16 is also conserved in Gliomas as TRRAP has also been 
demonstrated to promote differentiation in glioma models (133). However, this 
correlative relationship requires investigation in future studies. 
ITIH1 encodes a component of the heavy chain of the inter-alpha-trypsin inhibitor 
complex, which is secreted by hepatocytes into the blood to prevent aberrant protease 
activity (218). Expression of ITIH1 was found to be downregulated in tumor compared to 
normal tissue in a cohort of ICC patients (219). Loss of ITIH1 is implicated in a myriad 
of inflammatory diseases including Rheumatoid Arthritis, Crohn’s Disease and 
Ulcerative Colitis (218). Functional studies have not elucidated the function of ITIH1 in 
hepatocytes, however based on the low expression of ITIH1 in other inflammatory 
diseases, we hypothesize that loss of ITIH1 in hepatocytes can trigger a pro-inflammatory 
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environment that can contribute to HCC tumorigenesis. This hypothesis can be tested in 
future studies.  
Given that BAAT, RDH16 and ITIH1 are required for integral hepatocyte 
functions, increased expression of TRRAP perhaps represses these genes in order to 
mediate the transformation from normal hepatocytes into HCC. Furthermore, increased 
expression of all three genes confers a favorable prognosis to HCC patients. Taken 
together the data suggests that all three genes can contribute to tumorigenesis when 
repressed by TRRAP in HCC cells.  
The function of TRRAP in other cancer types is unclear. A previous study found 
that TRRAP depletion induces differentiation of brain tumor-initiating cells derived from 
GBM patients, partially due to reduced cyclin A2 expression and S/G2 progression (194). 
We found that cyclin A2 is also a TRRAP-activated gene in HCC, although we did not 
observe a strong positive correlation between cyclin A2 and TRRAP mRNA expression 
in TCGA GBM patient samples. However, we found an overlap in TRRAP-activated 
genes (14 of the 22) between GBM and HCC. Thus, TRRAP may regulate a similar set of 
genes between different cancer types. However, unlike in HCC, TRRAP mRNA 
expression is not a prognostic predictor in either GBM or other cancers (Figure 2.13C 
and based on data from the Human protein atlas). TRRAP mutations are reported in 
several cancer types, but their effects have not been studied.   
In this chapter, we also demonstrate that loss of TRRAP results in loss of the 
HAT cofactors KAT2A and KAT5. Interestingly, there was no change in mRNA levels 
of both KAT2A and KAT5. Studies have demonstrated that KAT2A can be ubiquitinated 
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and degraded by the ubiquitin proteasome system (220) and that P300 degradation 
resulted in lysosomal degradation of KAT5 (221). Given that both KAT2A and KAT5 
form complexes with TRRAP we hypothesized that loss of TRRAP resulted in 
destabilization of the complex and subsequent degradation of KAT2A and KAT5. 
However, this was not the case as treating cells with the MG132, a proteasome inhibitor, 
and chloroquine, a lysosomal degradation inhibitor, failed to rescue protein levels of both 
KAT2A and KAT5.  
Taken together with the fact that mRNA levels of both KAT2A and KAT5 remain 
steady, the data suggested that the decreased protein expression of KAT2A and KAT5 
may be due to failure to translate the transcripts. However, further experiments are 
needed to test this hypothesis. Given that other transcripts are being translated, it is 
reasonable to speculate that this regulation is not due to loss of a universal translation 
factor such as EIF4 and was instead transcript specific. Specificity for translational 
regulation can be conferred via the 5’ and 3’ UTRs. 5’UTR and 3’UTRs of transcripts 
contain binding sites for RBPs. Binding of RBPs at the 5’UTR or 3’UTR mediates 
capping, polyadenylation, export out of the nucleus and recruitment to the ribosome for 
translation (222). Additionally, aberrations in levels of RNA Binding Proteins (RBPs) 
can also reduce translation in a transcript specific manner. One possibility is that TRRAP 
loss results in decreased expression of an RBP that is responsible for translation of the 
KAT2A and KAT5 transcripts.  
The loss in KAT2A and KAT5 protein but not mRNA could also be due 
aberrations in polyadenylation and in UTR lengths. Previous studies have demonstrated 
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that an increase in the 3’UTR length, due to aberrant polyadenylation, can decrease 
translation of a transcript (223). Future studies can determine changes in the 3’UTR 
length of the KAT2A and KAT5 transcripts after TRRAP depletion via 3’ RACE.  
Overall future studies can utilize two experiments to understand how translation 
of these transcripts is disrupted. The first experiment would be to determine localization 
of the transcript via RNA-FISH or polysome isolation. If the transcripts are localized 
predominantly in the nucleus, it suggests that TRRAP depleted cells are unable to cap 
and tail KAT5 and KAT2A transcript or require another RBP to mediate efficient nuclear 
export. If the transcripts are found within the polysome, it suggests that TRRAP depleted 
cells are unable to initiate translation of these transcripts. The second study needs to 
analyze the 3’ and 5’ UTR sequences of KAT2A and KAT5 in order to identify putative 
RBP domains or microRNA binding domains and identify the RBP protein(s) and/or 
microRNAs that can bind to the transcript and regulate its translation. Once a candidate 
list is generated, this list can be cross referenced with the RNA-seq data from TRRAP 
depleted cells to further home in on the candidate RBP(s).  
The work in this chapter also identified that depletion of KAT5 reduces 
proliferation of HCC cells. KAT5’s main function is as a histone acetyltransferase 
however work in mouse ES cells also shows that KAT5 plays a repressive role in 
differentiation and development via binding of the P400-KAT5 complex to H3K4me3 
marks (146). In line this HAT independent function, mutation of two residues (Gln-377 
and Gly-380) to glutamic acid in the acetyl CoA binding site of KAT5 abolishes its HAT 
catalytic activity (189). Previous studies have demonstrated that the HAT activity of 
 50 
KAT5 is required for DNA damage sensing via ATM (224) as acetylation, firstly, relaxes 
the chromatin thereby making it more accessible for DNA repair enzymes (147) and, 
secondly, mediates activation of ATM to initiate signaling of the DNA damage response 
(224). However recent studies have demonstrated that because of the large size of the 
KAT5 complex, catalytically inactive KAT5 can still repress gene expression by binding 
DNA thereby limiting chromatin accessibility (225).  
The role of catalytically inactive KAT5 in tumorigenesis remains unclear. 
Analysis of TCGA data reveals that the major aberration of KAT5 in HCC, comprising 
5% of cases, is amplification. Missense mutations are found in <1% of HCC and the 
mutations that do occur are not within the acetyl CoA binding site (data not shown)(14). 
In this chapter I demonstrate that in the absence of KAT5, HCC proliferation is impaired 
by decreased expression of key genes involved in mitotic progression. Given that KAT5 
activates transcription of mitotic progression genes in our model, I would expect that the 
catalytic HAT function of KAT5 would be required for HCC progression.  
Overall in this chapter I identify TRRAP and KAT5 as a mediator of proliferation 
in HCC cells. The results provide an important discovery for a role for TRRAP and its 
co-factor KAT5 in activating downstream mitotic genes in HCC cell growth. Our 
mechanism identifies the TRRAP complex as a potential therapeutic target in HCC. 
Given that the crystal structure of the TRRAP/KAT5 complex was recently characterized 
in yeast, it may be possible to target the interaction between TRRAP and KAT5 and 
disrupt the histone acetyltransferase activity of the complex (226). Moreover, small 
molecule inhibitors targeting KAT5 and mitotic proteins are currently under development 
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(41, 227). Future work should determine how TRRAP overexpression and mutations 
affect its function to understand the extent and significance of TRRAP alterations in other 
cancers. Moreover, because in vivo models of TRRAP consist of only genetic knockouts, 
it will be critical to establish constitutively-active TRRAP and mutant TRRAP models to 
further characterize its role in tumor development.  
 
Materials and Methods 
Cell culture 
Huh7 and SNU475 cells were provided by Dr. Scott Lowe. Huh7 cells were 
cultured in DMEM. SNU-475 cells were cultured in RPMI supplemented with 10 mM 
HEPES, 1 mM sodium pyruvate, and 4500 mg/L glucose. Hep3B and HepG2 cells were 
provided by Dr. Junwei Shi and cultured in MEM. All cell lines were grown in media 
supplemented with 10% FBS and 1% penicillin-streptomycin and maintained in a 37 C 
incubator with 5% CO2. Huh7, HepG2, Hep3B and SNU-475 cells were authenticated 
using ATCC’s cell authentication service. MG132 and chloroquine were purchased from 
Millipore Sigma.  
 
Kinome CRISPR screen  
The human kinome CRISPR pooled library was a gift from John Doench and 
David Root (Addgene #1000000083). The library was amplified according to Addgene’s 
library amplification protocol. Lentivirus containing the kinome library was packaged 
using 293fs cells. For each cell line, duplicates were performed. For each replicate, 2 × 
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107 cells were infected with lentivirus. Huh7 and Hep3B cells were selected with 2 
µg/mL puromycin for 3 days and HepG2 cells were selected with 4 µg/mL puromycin for 
4 days. For each sample, genomic DNA was harvested from at least 6 × 106 cells using 
the PureLink Genomic DNA mini kit (Thermo Fisher Scientific, Waltham, MA). sgRNA 
was amplified using Phusion flash high-fidelity PCR master mix (Thermo Fisher 
Scientific). All sequencing datasets were evaluated using FastQC (version 0.11.2) to 
ensure high quality. Depleted genes were identified as previously described (228). 
 
Bioinformatics analysis  
To analyze gene expression levels between tumor and non-tumor tissues, the 
GSE14520 (20) and TCGA HCC data sets were used. Gene expression data of tumor 
(n=225) and non-tumor tissue (n=220) in the GSE14520 data set were analyzed using 
GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/). Briefly, P-values were calculated 
using moderated t-statistics and adjusted using the Benjamini-Hochberg method. Gene 
expression data of TCGA HCC tumors and matched non-tumors (n=50) were obtained 
from the UCSC Xena Browser (http://xena.ucsc.edu/) and analyzed using the Wilcoxon 
signed-rank test. The list of genes that predict prognosis of HCC patients was obtained 
from the Human Protein Atlas (version 18, https://www.proteinatlas.org/) . For survival 
analysis, FKPM values and survival data were obtained from the Human Protein Atlas 
and cBioPortal (http://www.cbioportal.org/) respectively. The LEC data is available on 
GEO with accession numbers GSE1898 and GSE4024 (229, 230). FKPM values were 
grouped in tertiles and the highest and lowest tertiles were designated as ‘high 
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expression’ and ‘low expression’ groups. P-values were calculated using the log-rank 
Mantel-Cox test with GraphPad Prism. TRRAP mutations and copy-number alterations in 
HCC were obtained from cBioPortal. For gene correlation analyses, correlation data from 
the TCGA HCC (n=360) and GBM (n=136) data sets were obtained from cBioPortal. 
Briefly, gene expression data were analyzed using Spearman’s correlation analysis. For 
GO analyses, the list of genes was analyzed using the PANTHER overrepresentation test 
and annotated with the GO Ontology database (released 2018-10-08). P-values were 
calculated using Fisher’s Exact test and corrected by the Benjamini-Hochberg method. 
To determine KAT5 binding sites, we analyzed ChIP-sequencing data from GSE69671 
(203).   
 
sgRNA design and lentivirus infection 
sgRNAs were designed using 
https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design, cloned into the 
LentiCRISPRv2 backbone (Addgene #52961) and packaged into lentivirus using 293fs 
cells. HCC cells infected with lentivirus were selected with puromycin for 2-4 days. 
Sequences of sgRNAs are listed in Table 2.4.  
 
Immunoblot Analysis  
Cells were washed twice with ice-cold PBS and harvested in RIPA buffer (Boston 
Bioproducts, Ashland MA) supplemented with protease (Roche, Indianapolis, IN) and 
phosphatase inhibitor cocktails (Thermo Fisher Scientific). The concentration of protein 
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was measured using the BCA assay (Thermo Fisher Scientific). For each sample, 25 µg 
of protein was loaded onto an SDS-PAGE gel. The following antibodies were used to 
probe against: TRRAP (#3967; Cell Signaling Technology, Danvers, MA), KAT2A 
(#3305; Cell Signaling Technology), KAT5 (sc-166323; Santa-Cruz Biotechnology, 
Dallas, TX), NIK (#4994; Cell Signaling Technology), LC3B (#2775; Cell Signaling 
Technology), TOP2A (#12286; Cell Signaling Technology), GAPDH (MAB374; 
Millipore Sigma, Burlington, MA), Hsp90 (#610419; BD Bioscience, San Jose, CA), and 
Flag (#2368; Cell Signaling Technology and #F1804; Millipore Sigma). Bands were 
visualized with an immunofluorescent secondary antibody (LICOR) using the Odyssey 
Imaging system.   
 
Cell growth and colony formation assays  
To measure cell growth, cells were seeded onto 96-well plates. CellTitre-glo 
assay (Promega, Madison, WI) was performed according to the manufacturer’s protocol. 
The growth of cells at day 3 and day 5 was normalized to measurements taken one day 
after the cells were plated. Each repeat was averaged between 6 wells. For colony 
formation assays, Huh7 and SNU-475 cells were seeded at 3000 and 2000 cells per well 
respectively onto 6-well plates. After 11 days, cells were fixed with 4% formalin and 
stained with 0.5% crystal violet. All experiments were repeated three times.  
 
RNA extraction and RT-qPCR  
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RNA was extracted from cells using the RNeasy mini kit (Qiagen, Germantown, 
MD) and DNA was removed by on-column DNase digestion (Qiagen) according to the 
manufacturer’s protocol. One microgram of RNA was used to synthesize cDNA using the 
high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. RT-qPCR analyses were performed using SsoFast EvaGreen 
supermix (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol and GAPDH 
was used as a control. Primer sequences used for qRT-PCR are listed in Table 2.5.  
 
 
 
Animal Studies 
Female 6-week-old NCRNu/Nu mice were purchased from Taconic Bioscience 
(Rensselaer, NY) and injected in the right or left flank with 1x106 TRRAP stable 
knockdown Huh7 cells. Cells were resuspended in PBS and mixed in a 2:1 ratio with 
matrigel (Westnet Inc., Canton, MA) to a final volume of 200 L. Tumor size was 
measured by calipers and volume was calculated using the formula Volume=((π)(Length)
〖(Width^2))/6.   
For induction of HCC in vivo, sgRNAs against p53 and Trrap were cloned into a 
previously described Sleeping Beauty Cas9 plasmid (231). Plasmids were delivered in 
vivo via Hydrodynamic tail vein injection into 6-week-old female C57/Bl6 mice as 
previously described (104).   
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All mice were housed in JAG75 (Allentown) ventilated cage systems with 1/4″ 
Bed-o’Cobs (Andersons Lab Bedding) in facilities accredited by the American 
Association for Laboratory Animal Care (AALAC) at the University of Massachusetts 
(UMass) Medical School. Mice were provided with nestlets (Ancare) and Bed-r’Nests 
(Andersons Lab Bedding) and maintained in a pathogen‐free animal facility at 22°C 
under the 12‐hour light/dark cycle. Mice were injected during the light cycle and were 
not fasted prior to injection. Mice were maintained on a standard diet of Prolab Isopro 
RMH 3000 (LabDiet) throughout the course of the experiment. All animal protocols were 
approved by the UMass Medical School Institutional Animal Care and Use Committee 
(IACUC) and comply with all relevant federal guidelines and institutional policies.   
 
Immunohistochemistry  
Murine livers were fixed in 4% or 10% (v/v) formalin overnight and embedded in 
paraffin. 4 μm liver sections were stained with hematoxylin and eosin (H&E) or with 
antibodies using standard immunohistochemistry protocols. The following antibodies and 
dilutions were used: 1:100 anti-CD4 (Thermo-fisher) and 1:400 anti-F4/80 (CST).  
 
RNA-sequencing and bioinformatics analysis  
Ribosomal RNA was depleted and RNA-sequencing libraries were prepared as 
previously described (25). The libraries were quantified using the KAPA Library 
Quantification Kit (Kapa Biosystems, Wilmington, MA) and sequenced using the 
Illumina NextSeq 500 system. RNA-seq reads from each sample were aligned using 
 57 
STAR (version 2.5.2b) (232) against the GRCh37/hg19 human reference genome. Gene 
expression was quantified through RSEM (v1.2.31) (233) with GENCODE V19 gene 
annotation. DESeq2 (1.22.0) (234) was employed to identify differentially expressed 
genes using raw read counts quantified by htseq-count(235). 
 
Immunofluorescence 
Cells were plated onto glass coverslips overnight and fixed with 4% 
Paraformaldehyde (Fisher Scientific) for 15 minutes and permeabilized with 0.3% Triton 
X-100 (Millipore Sigma) for 10 mins. Coverslips were blocked with blocking solution 
comprised of 7% Fetal Bovine Serum (Thermo Fisher) and 3% Bovine Serum Albumin 
(Millipore Sigma) for 1 hour at room temperature. Coverslips were then incubated with 
the following antibodies at 1:100 for 1 hour at room temperature: Rabbit-anti-TRRAP 
(#PA5-65866; Thermo Fisher Scientific) and mouse-anti-TIP60 (#sc-166323; Santa 
Cruz). Coverslips were then incubated with the following secondary antibodies for 1hour 
at room temperature at 1:500: Alexa Fluor 488 goat anti-mouse IgG (#A11001; Life 
Technologies) and Alexa Fluor 568 donkey anti-rabbit IgG (#A10042; Life 
Technologies). Cells were then stained with 5 µg/mL DAPI (#D1306; Fisher Scientific). 
Images were captured at 63x using a Leica DMi8 microscope. 
 
Luciferase promoter assay 
A 500 bp region spanning the transcriptional start site of TOP2A promoter from 
Huh7 cells was cloned using primers listed in Table 2.6 and ligated to the pBV-luc vector 
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(Addgene #16539). A 500bp region of the TOP2A ORF was also cloned using primers 
listed in Table 2.6 into the pBV-luc vector and served as a negative control. Flag-TRRAP 
was purchased from Addgene (#32103). Flag-KAT5 was purchased from Genecopoeia 
(#EX-Z5325-Lv101) and the Flag-KAT5 sequence was subcloned into lentiCas9-blast 
(Addgene #52962) to replace the Cas9 sequence. 293fs cells were plated onto 6-well 
plates and transfected with 1 µg each of the indicated plasmids and pRL-SV40P 
(Addgene #27163) using lipofectamine 3000 (Invitrogen) for 48 hours. Cells were then 
trypsinized and re-plated onto 96-well plates, and luciferase activity was measured using 
the Dual-glo luciferase assay system (Promega) according to the manufacturer’s protocol. 
For each sample, luciferase activity was measured by normalizing firefly luciferase 
activity to Renilla luciferase activity and averaged between 6 wells. Fold change was 
calculated with respect to a pBV-luc negative control plasmid  
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Figure 2.1. A kinome CRISPR screen identifies genes essential for HCC cell growth.  
A) Venn diagram depicting overlapping depleted gene in three HCC cell lines and table 
of 10 most significant annotation clusters from GO analysis of the 31 depleted genes B) 
mRNA levels of candidate genes in non-tumor and tumor samples in the GSE14520 data 
set. P-values were calculated using moderated t-test. Black lines indicate the geometric 
mean of each group. C) Kaplan Meier curves of TCGA liver cancer patients with high or 
low expression of the candidate genes in A. P-values were calculated using the log-rank 
Mantel-Cox test.  D) Genes from the CRISPR screen were ranked by their false discovery 
rate, the 8 candidate genes are indicated.  
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Figure 2.2. Identification of TRRAP as a potential oncogene in HCC. 
A) mRNA levels of TRRAP in non-tumor and tumor samples from the GSE14520 (left) 
and TCGA (right) data sets, p-values were calculated using moderated t-test and 
Wilcoxon signed-rank test respectively. Black lines indicate the geometric mean of each 
group. B) Kaplan Meier curves of HCC patients from the TCGA (left) and NIH 
Laboratory of Experiment Carcinogenesis (LEC, right) cohorts with high (TCGA n=115 
and LEC n=31) or low (TCGA n=118 and LEC n=31) TRRAP expression. P-values were 
calculated using the log-rank Mantel-Cox test. *p < 0.05, ***p < 0.001. C) p53 status in 
TRRAP high (n=115) and TRRAP low (n=118) TCGA HCC patient samples. P-value 
was calculated by Fisher’s exact test. D) TRRAP mRNA up-regulation, copy-number 
alterations and/or mutations in TCGA patient HCC samples. E) Ingenuity Pathway 
N
 (n
=2
20
)
T 
(n
=2
25
)
3
4
5
6
7
8
L
o
g
2
 m
R
N
A
TRRAP (GSE14520)
***
C 
N
 (n
=5
0)
T 
(n
=5
0)
8
9
10
11
12
L
o
g
2
 m
R
N
A
TRRAP (TCGA) 
*
p53 wt p53 mut
0
20
40
60
80
100
N
o
. 
o
f 
p
a
tie
n
ts
High TRRAP
Low TRRAP
p = 0.002
A B 
D 
TCGA HCC patients (n=360)  
E 
 61 
analysis of genes that were positively correlated with TRRAP expression (Spearman’s 
correlation> 0.3) in TCGA HCC samples.  
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Figure 2.3. Loss of TRRAP impairs cell growth in HCC cells. 
A) TRRAP protein expression in Huh7, Hep3B, SNU-475 and HEPG2 cells infected with 
non-target (sgNT) and 3 individual TRRAP sgRNAs (sgTRRAP). HSP90 was used as a 
loading control. B and C) Cell growth and colony formation of Huh7, Hep3B, and SNU-
475 and HEPG2 cells infected with sgNT and sgTRRAP. B) Cell growth was measured 
at 1, 3, and 5 days after plating using the CTG assay and normalized to day 1. C) Cells 
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were stained with crystal violet. Data was presented as mean ± SD; p-values were 
calculated by comparing to sgNT, *p < 0.05, **p < 0.01, ***p < 0.001 (student’s t test). 
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Figure 2.4. Loss of TRRAP results in loss of HAT cofactors KAT2A and KAT5. 
A) Immunofluorescence images of Huh7 and SNU-475 cells stained with DAPI (blue), 
anti-KAT5 (green) and anti-TRRAP (red) antibodies. B) Protein levels of KAT2A and 
KAT5 in HUH7 and SNU-475 cells infected with sgNT and sgTRRAP. GAPDH was 
used as a loading control. C) mRNA levels of KAT2A and KAT5 in HUH7 and SNU-
475 cells infected with sgNT and sgTRRAP. D) Huh7 cells were infected with the 
indicated sgRNAs, then treated with 2.5 μM MG132 or 50 μM chloroquine for 17 hours. 
Increased expression of NIK and LC3B were used as positive controls to show inhibition 
of proteasomal and lysosomal protein degradation. GAPDH was used as a loading 
control. 
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Figure 2.5. Loss of histone acetyltransferase KAT5 impairs growth in HCC cells. 
A) Western blot of KAT2A, KAT5 levels in Huh7 cells infected with sgNT, sgKAT2A 
and sgKAT5. GAPDH was used as a loading control.  B) Western blot of KAT2A, KAT5 
levels in SNU475 cells infected with sgNT, sgKAT2A and sgKAT5. GAPDH was used 
as a loading control. D) Colony formation, of Huh7 and SNU475 cells infected with 
sgNT, sgKAT2A, and sgKAT5. Cells were stained with crystal violet.  
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Figure 2.6. Loss of TRRAP and KAT5 impairs HCC growth and initiation in vivo. 
A) Tumor weight at day 30 (left) and tumor sizes (right) in nude mice subcutaneously 
injected with Huh7 cells. P-values were calculated using Mann-Whitney test against the 
sgNT group. Data was presented as mean ± SD; p-values were calculated by comparing 
to sgNT, *p < 0.05, **p < 0.01, ***p < 0.001, NS = not significant (student’s t test).  B) 
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Overview of three plasmids injected into mice via hydrodynamic tail vein injection to 
generate HCC tumors. The CRISPR-sleeping beauty plasmid plasmid contains S. 
pyogenes Cas9 (SpCas9) flanked by two nuclear localization signals (NLS) that is driven 
by a chicken beta-actin promoter (CBA) and an sgRNA (encoding either a Non-Target or 
Trrap sgRNA) driven by a U6 promoter. This entire construct is flanked by two sleeping 
beauty (SB) cassettes for integration. A second plasmid contains an sgRNA against P53 
driven by a U6 promoter and a S. pyogenes Cas9 (SpCas9) flanked by two nuclear 
localization signals (NLS). The third plasmid contains the human MYC cDNA flanked 
by two SB cassettes. C) Gross images of the entire liver and H&E staining of liver 
sections four weeks after injection with sgNT or sgTRRAP along with IHC analyses of 
CD4 and F480 in sgTRRAP tumors. 
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Figure 2.7. Analysis of genes regulated by TRRAP in HCC 
A) Gene ontology (GO) analysis of down-regulated genes in sgTRRAP cells compared to 
non-targeting control. The 10 most significant annotation clusters are shown here. B) 
Gene ontology (GO) analysis of up-regulated genes in sgTRRAP cells compared to non-
targeting control. The 10 most significant annotation clusters are shown here.  C) 
Pipeline for identifying HCC-relevant TRRAP target genes. D) GO analysis of the 22 
TRRAP-activated genes identified in B. 
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Figure 2.8. Increased expression of TRRAP-activated genes confers poor prognosis 
in HCC patients. 
Kaplan Meier curves of TCGA HCC patients with high or low expression of TRRAP-
activated genes listed in Table 1. P-values were calculated using the log-rank Mantel-Cox 
test. The Kaplan Meier curve of BUB1B is shown in Figure 2.1C.  
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Figure 2.9. Positive correlation between mRNA expression of TRRAP and TRRAP-
activated genes in HCC patient samples. 
mRNA levels were downloaded from the TCGA HCC data set (n=360). Correlation was 
determined using Spearman’s correlation analysis.  
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Figure 2.10. Identification of genes repressed by TRRAP. 
A) Kaplan Meier curves of TCGA HCC patients with high or low expression of genes 
listed in Supplementary Table 3. B) Negative correlation between mRNA expression of 
TRRAP and TRRAP-inhibited genes in the TCGA HCC data set (n=360). Correlation was 
determined using Spearman’s correlation analysis.  
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 2.11. TRRAP/KAT5 activates transcription of mitotic genes. 
A) KAT5 binding analysis at the transcriptional start sites (TSS) of the 22 TRRAP-
activated genes using published ChIP-seq data (top). KAT5 binds to the TSS of TOP2A 
(bottom). B) mRNA levels of 6 TRRAP-activated genes in Huh7 cells infected with the 
indicated sgRNAs as measured by qRT-PCR. C) mRNA levels of 6 TRRAP-activated 
genes in SNU-475 cells infected with the indicated sgRNAs as measured by qRT-PCR.  
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Figure 2.12. KAT5 binds to the transcriptional start sites (TSS) of TRRAP-activated 
genes. 
Analysis of published ChIP-sequencing data for KAT5 binding sites in mouse embryonic 
stem cells at TRRAP-activated genes (blue) identified in Table 1. Of note, no prominent 
peaks were observed at the TSS of Bub1b, Dlgap5 and Nsd2. 
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Figure 2.13. Loss of TRRAP and KAT5 reduces proliferation through down-
regulation of TOP2A. 
A) Correlation between TRRAP and TOP2A mRNA expression in the TCGA HCC data 
set (n=360) was determined using Spearman’s correlation analysis (left). B) mRNA 
expression of TOP2A in non-tumor (N) and HCC (T) samples in the GSE14520 (left) and 
TCGA HCC (right) data sets, p-values were calculated using moderated t-test and the 
Wilcoxon signed-rank test respectively. Kaplan Meier curves of TCGA HCC patients with 
high or low TOP2A expression (right), p-value was calculated using the log-rank Mantel-
Cox test. C) Correlation between TRRAP and TOP2A mRNA expression in the TCGA 
GBM data set (n=136) was determined using Spearman’s correlation analysis (left). Kaplan 
Meier curve of TCGA GBM patients with high (n=50) or low (n=51) TRRAP expression 
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(right). P-value was calculated using the log-rank Mantel-Cox test. D) Protein levels of 
TOP2A after knockdown with indicated sgRNA in SNU-475 and HUH7 cell lines. 
GAPDH was used as a loading control.  
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Figure 2.14. Loss of TOP2A Reduces Proliferation in HCC cells. 
A) Top2A promoter luciferase assay in 293fs cells transfected with the indicated 
plasmids. Luciferase activity was normalized to the negative control pBV-luc. B) Protein 
levels of TOP2A in Huh7 and SNU-475 cells infected with the indicated sgRNAs. 
GAPDH was used as a loading control. C) Colony formation of Huh7 and SNU-475 cells 
infected with sgTOP2A. 
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Gene 
Symbol 
Entrez gene name 
RNA-seq 
sgTRRAP vs sgNT 
GSE14520 HCC/ 
non-tumor tissue 
TCGA HCC co-
expressed with 
TRRAP 
Fold 
change 
P-value 
Fold 
change 
P-value 
Spearman's 
coefficient 
P-value 
ASPM Abnormal spindle 
microtubule assembly 
0.46 1.8E-02 8.22 8.3E-112 0.357 1.7E-11 
BUB1B BUB1 mitotic checkpoint 
serine/threonine kinase B 
0.42 2.6E-07 3.33 1.4E-73 0.428 2.0E-16 
CCNA2 Cyclin A2 0.35 2.2E-03 2.45 1.7E-59 0.309 9.8E-09 
CENPF Centromere protein F 0.39 5.7E-03 5.25 3.9E-101 0.452 2.3E-18 
DBF4 DBF4 zinc finger 0.46 8.4E-06 2.41 2.6E-71 0.48 7.2E-21 
DLGAP5 DLG associated protein 5 0.42 2.9E-06 2.49 6.9E-60 0.316 3.9E-09 
EZH2 Enhancer of zeste 2 
polycomb repressive 
complex 2 subunit 
0.38 5.5E-07 3.41 2.4E-78 0.408 6.1E-15 
FOXM1 Forkhead box M1 0.38 4.5E-08 2.27 5.9E-67 0.414 2.2E-15 
KIF20A Kinesin family member 
20A 
0.23 1.2E-04 3.24 3.8E-80 0.332 5.9E-10 
KIF4A Kinesin family member 4A 0.41 5.5E-06 2.70 1.4E-69 0.314 5.3E-09 
MAD2L1 Mitotic arrest deficient 2 
like 1 
0.45 1.2E-06 2.88 4.9E-62 0.321 2.3E-09 
MCM2 Minichromosome 
maintenance complex 
component 2 
0.38 1.9E-07 3.13 6.3E-69 0.342 1.5E-10 
MCM4 Minichromosome 
maintenance complex 
component 4 
0.46 1.0E-06 3.03 3.2E-72 0.53 5.9E-26 
MKI67 Marker of proliferation ki-
67 
0.41 4.3E-02 2.38 9.5E-51 0.403 1.6E-14 
NSD2 Nuclear receptor binding 
SET domain protein 2 
0.46 3.5E-06 2.10 3.0E-61 0.605 2.6E-35 
PRC1 Protein regulator of 
cytokinesis 1 
0.40 4.9E-09 5.49 9.2E-106 0.378 8.2E-13 
RACGAP1 Rac gtpase activating 
protein 1 
0.39 1.2E-07 4.66 2.5E-108 0.333 5.1E-10 
RAD51AP1 RAD51 associated protein 
1 
0.50 3.3E-04 2.59 2.0E-62 0.411 4.1E-15 
TOP2A DNA topoisomerase II 
alpha 
0.34 5.2E-03 8.27 8.5E-98 0.406 8.6E-15 
TPX2 TPX2, microtubule 
nucleation factor 
0.37 5.6E-08 3.22 7.3E-71 0.317 3.6E-09 
TTK TTK protein kinase 0.47 2.0E-05 3.22 9.7E-69 0.306 1.4E-08 
XPOT Exportin for trna 0.47 1.5E-08 2.44 1.9E-62 0.485 2.5E-21 
 
Table 2.1 List of genes that are down-regulated in the absence of TRRAP and identified 
from our bioinformatic analyses. 
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Table 3. List of genes that are up-regulated in the absence of TRRAP and identified from 
our bioinformatics analyses.  
Gene 
Symbol 
Entrez Gene Name 
RNA-seq  
sgTRRAP vs sgNT 
GSE14520 HCC/ 
non-tumor tissue 
TCGA HCC co-
expressed with 
TRRAP 
Fold 
change 
P-value 
Fold 
change 
P-value 
Spearman's 
coefficient 
P-value 
BAAT bile acid-CoA:amino acid N-
acyltransferase 
10.79 4.0E-40 0.41 5.4E-22 -0.309 9.7E-09 
ITIH1 inter-alpha-trypsin inhibitor 
heavy chain 1 
2.05 2.9E-03 0.41 1.1E-32 -0.4 2.4E-14 
RDH16 retinol dehydrogenase 16 3.54 4.9E-02 0.14 1.3E-73 -0.301 2.5E-08 
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Table 4. TRRAP regulates a similar set of genes in HCC and GBM.  
Gene symbol Spearman's Correlation p-Value 
ASPM 0.484 2.6E-08 
BUB1B 0.315 7.6E-04 
CCNA2 0.117 2.8E-01 
CENPF 0.554 5.2E-11 
DBF4 0.139 1.9E-01 
DLGAP5 0.211 3.3E-02 
EZH2 0.408 5.7E-06 
FOXM1 0.437 8.5E-07 
KIF20A 0.324 5.0E-04 
KIF4A 0.418 2.9E-06 
MAD2L1 -0.084 4.5E-01 
MCM2 0.393 1.3E-05 
MCM4 0.544 1.4E-10 
MKI67 0.590 1.3E-12 
NSD2 0.569 1.2E-11 
PRC1 0.347 1.6E-04 
RACGAP1 0.136 2.0E-01 
RAD51AP1 -0.036 7.7E-01 
TOP2A 0.319 6.3E-04 
TPX2 0.375 3.8E-05 
TTK 0.177 8.2E-02 
XPOT 0.205 3.9E-02 
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Table 5. sgRNA sequences used in Chapter II  
sgRNA name Sequence (5'-3') 
sgTRRAP.1 ACTCCTGATACAAGAGATCG 
sgTRRAP.2  CTTGATCCGCCACTATACGA 
sgTRRAP.3 CCACTGGGGATCGTTCAGTG 
sgKAT2A.1 GCTGCTGGAAAAGTTCCGAG 
sgKAT2A.2 TCACCATGCCACCCTCAGAG 
sgKAT5.1 GATTGATGGACGTAAGAACA 
sgKAT5.2 ACCAGGCTGCCAGTCATGCG 
sgTOP2A.1 TGTACGCTTATCCTGACTGA 
sgTOP2A.2 GATGCTGCTATCAGCCTGGT 
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Primer name Sequence (5'-3') 
KAT2A-F CAGGGTGTGCTGAACTTTGTG 
KAT2A-R TCCAGTAGTTAAGGCAGAGCAA 
KAT5-F GGGGAGATAATCGAGGGCTG 
KAT5-R TCCAGACGTTTGTTGAAGTCAAT 
EZH2-F AATCAGAGTACATGCGACTGAGA 
EZH2-R GCTGTATCCTTCGCTGTTTCC 
GAPDH-F CTGGGCTACACTGAGCACC 
GAPDH-R AAGTGGTCGTTGAGGGCAATG 
KIF20A-F GCCAACTTCATCCAACACCT 
KIF20A-R GTGGACAGCTCCTCCTCTTG 
PRC1-F ATCACCTTCGGGAAATATGGGA 
PRC1-R TCTTTCTGACAGACGGATATGCT 
RACGAP1-F CTATGATGCTGAATGTGCGG 
RACGAP1-R AATCCTCAAAGTCCTTCGCC 
TOP2A-F ACCATTGCAGCCTGTAAATGA 
TOP2A-R GGGCGGAGCAAAATATGTTCC 
XPOT-F AGGGAGACGCTCATATCATGG 
XPOT-R TTGGGCGGCTTTATTTCGTAT 
 
Table 6 Primers used for qRT-PCR in Chapter II.  
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Primer name Sequence (5'-3') 
TOP2A 500bp F CTTACGCGTGCTAGCCCTCTCTAGTCCCGC 
TOP2A 500bp R TATATACCCGAATTCTTCACTACTAGCACC 
TOP2A neg control F CTTACGCGTGCTAGCGCCTGTAAATGAAAA 
TOP2A neg control R TATATACCCGAATTCTCTTTATATTAAAGG 
 
Table 7. Primers for cloning the TOP2A promoter  
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CHAPTER III 
Loss of TRRAP and its cofactor KAT5 triggers senescence in HCC independent of 
P53 and P21 
Introduction 
 In the previous chapter we identify TRRAP and its cofactor KAT5 as potential 
therapeutic targets in HCC. Loss of TRRAP and KAT5 reduces proliferation of HCC cell 
lines in vitro and in vivo. Furthermore, by cross referencing RNA-seq analysis of TRRAP 
depleted cells with data from HCC patients samples we identify that TRRAP and KAT5 
reduce expression of a subset of genes responsible for mitotic progression including 
TOP2A.  
 Studies in mouse models have demonstrated that TRRAP loss is embryonic lethal 
as embryos do not survive past the blastocyst stage (126). However, inducible tissue 
specific models have provided some insight into the differential effects of TRRAP loss in 
normal tissue. Depletion of TRRAP in the CNS resulted in impaired differentiation of 
neuronal progenitor cells due to failure to induce expression of stemness regulator genes 
such as Nanog, Oct4 and Sox2 (133). Interestingly, TRRAP depletion in B cells does not 
impair immunoglobin class switching but instead results in apoptosis of the cells (236). 
Finally, TRRAP loss in the liver impaired regeneration after CCl4 induced damage due to 
failure to induce cyclin A expression (132).    
 The work in this thesis is not the first to implicate the role of TRRAP in 
malignancies. Studies in glioblastoma revealed that loss of TRRAP increased 
differentiation of cultured glioblastoma tumor-initiating cells and impaired cell cycle 
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progression (194). Another study identified TRRAP as an oncogene in melanomas. The 
authors of this study demonstrated, via Hoechst staining, that depletion of TRRAP in 
melanoma cell lines resulted in apoptosis (190). Studies in lymphoma models have 
demonstrated that TRRAP promotes cell growth by stabilizing mutant isoforms of P53. 
In line with this, loss of TRRAP results in decreased proliferation of lymphoma cell lines 
in vitro (195). However, the work in this thesis is the first to examine the role of TRRAP 
in HCC and investigate how TRRAP loss results in decreased cell proliferation and tumor 
growth. 
 KAT5, a TRRAP HAT cofactor, plays essential roles in development as well as 
the resolution of DNA damage via acetylation of both histone and non-histone targets. 
KAT5 histone acetylation activity is required for ATM mediated detection and resolution 
of DNA damage(147). Moreover, KAT5 mediated acetylation of P53 is required for 
apoptosis in response to DNA damage (237). The majority of studies investigating KAT5 
in malignancies implicate it as a mediator of resistance to DNA damage therapies. 
Studies demonstrate that KAT5 is overexpressed in cisplatin resistant lung cancers, and 
that silencing of KAT5 sensitizes the cells to cisplatin treatment (238). Furthermore in 
androgen-resistant models of prostate cancer KAT5 is localized more in the nucleus 
compared to models of benign prostatic hyperplasia in which KAT5 is diffusely localized 
(239). In line with this, treatment with small molecule inhibitors of KAT5 such as 
NU9056 and TH1834 reduces proliferation of prostate and breast cancer cells in vitro 
(140). However, the consequences of KAT5 inhibition in HCC have not been studied.   
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In this chapter we demonstrate that loss of TRRAP/KAT5 and TOP2A induces 
senescence in HCC cells during. Moreover, the cells senescence during G2/M 
independent of DNA damage.      
 
Results 
Loss of TRRAP and KAT5 triggers senescence in HCC 
After inducing TRRAP loss via CRISPR/Cas9 mediated genome editing HUH7 
and SNU475 cells exhibit a distinct morphology—the cells became enlarged, flatter and 
resemble a fried egg (Figure 3.1A). These physical characteristics match those that are 
found in senescence cells (155). Indeed, loss of TRRAP in Huh7, Hep3B and SNU-475 
cells resulted in positive senescence-associated-beta-galactosidase (SA-β-gal) staining 
(Figure 3.1B and 3.1C). Furthermore, the molecular markers of senescence—p15, p16, 
and p21were increased in sgTRRAP cells compared to non-targeting controls in HUH7 
(Figure 3.2A), HEP3B (Figure 3.2B) and SNU-475 (Figure 3.3C) cell lines. Collectively, 
these data suggest that loss of TRRAP inhibits cell growth by inducing senescence.  
To determine whether TRRAP depletion induces senescence due to loss of 
KAT2A or KAT5 expression, we depleted KAT2A and KAT5 using CRISPR (sgKAT2A 
and sgKAT5) in Huh7 and SNU-475 cells (Figure 2.5A and 2.5B). We found that 
depletion of KAT5, but not KAT2A induced senescence similarly to TRRAP-depleted 
cells (Figure 3.3A and 3.3B). We also found a higher increase in p15 and p21 expression 
in sgKAT5 cells compared to non-targeting control and sgKAT2A cells (Figure 3.3C and 
3.3D).   
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TRRAP/KAT5 senescence is independent of canonical inducers of senescence  
Senescence can be triggered by multiple stimuli, such as DNA damage, 
replicative stress, activation of oncogenes, and oxidative stress (240). A key molecular 
event in induction of senescence is p53 activation and Rb hypophosporylation (241). 
However, Huh7 and SNU-475 cells are p53-mutant, and Hep3B cells are p53-null and 
Rb-null, suggesting that induction of senescence due to TRRAP and KAT5 depletion is 
independent of p53. In line with this, western blot analysis of P53 and Phospho-Rb in 
TRRAP depleted HUH7 cells showed a decline in levels of P53 and no change in the 
levels of phospho-Rb (Figure 3.4A). Based on Hayflick’s observations, low levels of 
telomerase expression (TERT) have also been demonstrated to induce senescence. 
However, TERT expression remained similar to controls in TRRAP and KAT5 depleted 
HUH7 cells (Figure 3.4B). Masashi Narita demonstrated that SAHF can also trigger 
senescence, however TRRAP depleted cells did not show increased DAPI foci compared 
to control HUH7 cells (Figure 3.4C). Since DNA damage can also induce senescence, we 
measured levels of the DNA damage mark H2A.X via flow cytometry and found no 
changes in the level of H2A.X compared to control cells (Figure 3.4D).    
 Since we observed an increase in the expression of p21, a p53 target that is also 
important in inducing senescence (241), we asked whether p21 is required to induce 
senescence in TRRAP- and KAT5-depleted cells. To this end, we co-depleted p21 and 
either TRRAP or KAT5 using CRISPR in Huh7 and SNU-475 cells via sequential 
infections (Figure 3.5A) and validated our knockouts via western blot (Figure 3.5B). We 
found that, even in the absence of p21, depletion of TRRAP and KAT5 inhibited colony 
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formation and induced senescence (Figure 3.5C and 3.5D). Using a similar sequential 
infection strategy, we also generated P53 and TRRAP/KAT5 double knockout HUH7 
cells (Figure 3.6A) and found no difference in induction of senescence in the absence of 
P53 (Figure 3.6B).  Taken together the data suggested that the canonical p53/p21 
pathway is not required for senescence in this context. 
 
Loss of TRRAP, KAT5 and TOP2A induces senescence during G2/M 
Previous studies have found that cells undergoing oncogene-induced senescence 
are arrested at G1 phase (24), but more recent evidence suggests that G2 arrest can also 
induce senescence (39). Since we found that the majority of TRRAP target genes regulate 
mitosis, we reasoned that TRRAP depletion may cause alterations in cell cycle 
progression. We analyzed cell cycle profiles using BrdU and PI staining and found that 
sgTRRAP and sgKAT5 cells accumulated at the G2/M phase. As expected, sgKAT2A 
cells did not accumulate at G2/M phase and displayed a cell cycle profile similar to non-
targeting controls (Figure 3.7A and Figure 3.7B).  
In line with our observations with TRRAP and KAT5, cells depleted of TOP2A 
also displayed phenotypes resembling TRRAP and KAT5 depletion. TOP2A knockouts 
stained positive for SA--gal (Figure 3.8A), had elevated expression of the senescence 
markers p21, and p16 (Figure 3.8B and 3.8C). Furthermore, we found that H2AX levels 
in sgTOP2A cells were similar to non-targeting controls, suggesting that DNA damage is 
not the cause senescence (Figure 3.9A). Finally, like TRRAP and KAT5 depleted cells, 
TOP2A depleted cells also arrested in G2/M (Figure 3.9B and 3.9C). Together, our 
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results suggest that TOP2A is a key mitotic target of TRRAP and KAT5 in regulating 
HCC cell growth. 
 
Discussion 
In this chapter we find that depletion of TRRAP, its cofactor KAT5 and its 
downstream target TOP2A reduces HCC proliferation by inducing senescence. In vitro, 
the cells stain positive for SA--gal and have elevated expression of the CDKIs p21 and 
p15. Furthermore, clearance of TRRAP depleted cells in vivo is correlated with the 
presence of F480+ cells and not CD4+ cells (Figure 2.6C). This is in line with previous 
observations that senescent cells are cleared by macrophages (182).     
TOP2A is thought to be the primary topoisomerase required for the decatenation 
of chromosomes during mitosis. In line with this, loss of TOP2A is embryonic lethal as 
zygotes arrest at the four to eight cell stage of development (242). Furthermore depletion 
of TOP2A in the fibrosarcoma cell line HT1080, results in tangled chromosomes, 
aberrant mitoses, aneuploidy, and cells undergo cell cycle arrest followed by cell death 
via apoptosis (243). Classically, Topoisomerase poisons have been demonstrated to 
induce apoptosis in various cancer models (244),  hence drugs like Etoposide and 
Doxorubicin have been core chemotherapies utilized for many cancer types. Surprisingly, 
the work in this thesis suggests that depletion of TOP2A results in senescence as opposed 
to apoptosis in HCC cells.  
Several studies have demonstrated that the consequences of topoisomerase 
inhibition are dependent on p53. When p53 was inhibited in the HT1080 fibrosarcoma 
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cell line after TOP2A inhibition, cells did not arrest and instead immediately underwent 
apoptosis (243). MCF-7 breast cancer cells with functional p53 enter senescence 
following doxorubicin treatment, whereas those lacking functional p53 undergo apoptosis 
(245). Similarly glioblastoma cells with intact p53, senesce in response to inhibition of 
topoisomerase I, whereas cells with disrupted p53 undergo apoptosis (246). A later study 
demonstrated that this effect was mediated by PTEN as glioma cells with intact PTEN 
underwent senescence through the AKT/ROS/p53/p21 signaling pathway whereas glioma 
cells that were PTEN deficient underwent apoptosis in response to radiation induced 
DNA damage (247).  
In addition to P53 status, a study in HCC revealed that treatment with 
Doxorubicin at high doses (10 uM) triggered apoptosis whereas treatment at low doses 
(40 nM) triggered senescence (248). This study demonstrated that treatment with low 
dose doxorubicin first triggered a “temporary senescence”, as marked by positive SA--
gal staining, but cells underwent caspase positive cell death 48 hours after the appearance 
of SA--gal. The authors suggested that treatment with high dose doxorubicin triggered 
apoptosis due to a temporary activation of the JNK and NFB pathways whereas NFB 
activation was sustained in low dose doxorubicin treated cells (248). Senescence 
associated with sustained NFB activation is in line with the autocrine effects of the 
SASP, however the factors that control the decision to senesce versus die in response to 
TOP2A inhibition in HCC remain unclear.    
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Interestingly, TRRAP and KAT5 depleted cells underwent senescence even in the 
absence of DNA damage as levels of H2A.X remained similar to sgNT and sgKAT2A 
cells. Previous studies have demonstrated that the TRRAP-KAT5 complex mediates 
DNA repair by two mechanisms. First the TRRAP-KAT5 complex acetylates the 
chromatin surrounding the site of damage thereby increasing accessibility to other repair 
proteins (147). Second, the TRRAP-KAT5 complex acetylates ATM in order to activate 
signaling down this DNA damage pathway (147). Therefore, the lack of detectable DNA 
damage in TRRAP and KAT5 depleted cells is likely due to loss of H2A.X deposition. 
However future experiments are required to determine if ATM signaling is attenuated in 
TRRAP and KAT5 depleted cells.  
Paradoxically we found a decline in P53 protein levels and no change in Rb 
phosphorylation in cell lines with functional P53 and Rb, such as HUH7 and SNU475, 
after TRRAP and KAT5 depletion. Moreover, we found that the HEP3B cell line which 
had deletions in both P53 and Rb senesced after TRRAP loss which further emphasized 
that senescence was independent of this pathway. Interestingly while generating the 
TRRAP/P53 double knockout cells we also observed that, unlike with TRRAP loss, loss 
of KAT5 did not result in a decrease in P53 protein levels (Figure 3.6A). A previous 
study in lymphoma and colon cancer models identified that one of the HEAT repeat 
regions of TRRAP was crucial for mutp53 stabilization as TRRAP shielded it from 
degradation via the MDM2-proteasome axis (195). Perhaps TRRAP is performing a 
similar role in HCC containing mutant P53, however future studies are needed to 
elucidate this possible mechanism. 
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Generally, p53 activation is a key event in senescence, but we discovered that 
TRRAP depletion induces senescence independent of the p53/p21 pathway in HCC cells. 
This finding has clinical implications for HCC treatment as 30% of HCC patients have 
p53 mutations (14) and p53 is more frequently mutated in HCC patients with high 
TRRAP expression (Figure 2.2C). Multiple studies have established various mechanisms 
for P53 independent senescence. Loss of VHL, a tumor suppressor, in MEFs induces 
senescence independent of P53 but dependent on Rb activation and P400 reduction (249). 
Senescence induction via Cdk2 deficiency was independent of p53 activity but depended 
on induction of P21 and P16 (250). SKP2 inactivation in lymphoid cancer models 
induced senescence independent of P53 but dependent on P21 and P27 (251). Even in 
HCC, treatment of cells with TGF- induced senescence independent of P53 but 
dependent on P21 and intracellular ROS accumulation (252). Overall, P53 independent 
senescence is a well-observed phenomenon but, as one would expect, the senescence 
inducing mechanisms were all dependent on Rb or CDKIs downstream of P53.  
Our study identified that TRRAP and KAT5 depletion triggered senescence 
independent of p53 and its downstream molecules p21 and Rb. A p53- and p21-
independent mechanism in immortalized human diploid fibroblasts has been described 
(253). In this previous study, loss of the histone acetyltransferase p300 induced 
senescence due to global H3 and H4 hypoacetylation resulting in SAHF and subsequent 
alterations in DNA replication timing and fork velocity (253). In the present study, we 
propose a different mechanism—TRRAP depletion leads to senescence due to 
downregulation of mitotic genes, such as TOP2A, and G2/M arrest that is also not 
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correlated with SAHF. This is distinct from cell cycle arrest as the cells are diploid, stain 
positive with SA-β-gal and have elevated expression of the CDKIs P16, P15 and P21. 
Our study is also the first to identify a p53, p21 independent mechanism of senescence in 
HCC.   
To determine how perturbation of this network induced senescence, we examined 
whether previously known inducers of senescence were activated in our cells. One of the 
key roles of the TRRAP/KAT5 complex is to mediate repair of DNA DSBs via 
acetylating the sites of damage and aiding in activation of ATM(147). Given that DNA 
damage has been previously demonstrated to induce senescence in various models (151), 
we hypothesized that TRRAP depleted cells senesced due to increased DNA damage. 
However, there was no change in H2A.X levels in TRRAP, KAT5 and TOP2A depleted 
HCC cell lines compared to non-target cells suggesting that our mechanism of senescence 
was independent of DNA damage. Furthermore, examination of telomerase levels and 
SAHF formation also showed no change upon TRRAP and KAT5 depletion.  
Studies out of the Berger lab elegantly demonstrated that in senescent cells, DNA 
fragments pinch off from the nuclei and are ejected into the cytoplasm (254). 
Furthermore, these cytoplasmic DNA fragments bind and activate cGAS/sting in order to 
trigger the SASP (255). Interestingly, overexpression of the DNases, DNase2 and 
TREX1, in senescent cells reduces SASP activation and can attenuate the induction of 
senescence (256, 257). Future studies can aim to elucidate whether senescence in TRRAP 
depleted cells is due to SASP induction via the presence of these cytoplasmic DNA 
fragments.  
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Various models of OIS and replicative senescence triggers arrest during G1(258), 
however, we conclude that TRRAP and KAT5 depletion induced senescence arrested 
cells during G2/M. The arrest in G2/M provides our first clue into identifying how loss of 
TRRAP and KAT5 induces senescence. G2/M arrest can arise from failure to replicate 
DNA during S phase. The most common reason for this is ATM activation secondary to 
DNA damage (258) however other mechanisms also exist. Previous studies have shown 
that depletion of nucleotide pools and histone pools can induce arrest during G2 as the 
genome is not able to replicate completely (258-260). The study implicating p300 HAT 
and senescence discussed earlier demonstrated that G2/M senescence in their model was 
due to decreased velocity across the replication fork secondary to limited chromatin 
accessibility (253). Another group has implicated aberrant regulation of Cyclin B as a 
mediator of G2/M arrest. For normal cell cycle progression Cyclin B must be activated, 
associate with CDK1 and translocate into the nucleus in order to initiate mitosis. 
Interestingly, cells will senesce during G2 due to failure to activate Cyclin B (either via 
p53 or p21) (261) or if there is a delay in translocation of cyclin B into the nucleus (261, 
262).  Finally, studies have also demonstrated that formation of other secondary 
structures in DNA such as Anaphase Bridges, G-quadruplexes, and R-loops can trigger 
replication stress and subsequent cell cycle arrest during G2 (263). In Chapter II of this 
thesis, we demonstrate that TRRAP loss reduces expression of genes involved in mitotic 
progression however future studies need to examine the mechanism(s) that enforces 
G2/M arrest and subsequent senescence in TRRAP depleted cells.   
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Taken together, the work in this chapter demonstrates that depletion of 
TRRAP/KAT5 or TOP2A triggers senescence in HCC cells independent of p53, p21 and 
other canonical mediators of senescence. Overall targeting the TRRAP/KAT5 complex or 
its downstream mitotic genes may be a pro-senescent strategy for treating HCC patients. 
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Materials and Methods 
 
Cell culture 
Huh7 and SNU475 cells were provided by Dr. Scott Lowe. Huh7 cells were 
cultured in DMEM. SNU-475 cells were cultured in RPMI supplemented with 10 mM 
HEPES, 1 mM sodium pyruvate, and 4500 mg/L glucose. Hep3B cells were provided by 
Dr. Junwei Shi and cultured in MEM. All cell lines were grown in media supplemented 
with 10% FBS and 1% penicillin-streptomycin and maintained in a 37oC incubator with 
5% CO2. Huh7, Hep3B and SNU-475 cells were authenticated using ATCC’s cell 
authentication service.  
 
sgRNA design and lentivirus infection 
sgRNAs were designed using 
https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design, cloned into the 
LentiCRISPRv2 backbone (Addgene #52961) and packaged into lentivirus using 293fs 
cells. HCC cells infected with lentivirus were selected with puromycin for 2-4 days. To 
generate double sgRNA-infected cells, sgNT and sgp21 were cloned into the 
LentiCRISPRv2 hygro backbone (Addgene #98291). SNU-475 and Huh7 cells infected 
with lentivirus were selected with 100 and 500 µg/mL hygromycin for 6 and 10 days 
respectively, then infected with sgNT, sgTRRAP, sgKAT5, and sgKAT2A, and selected 
with puromycin. Sequences of sgRNAs are listed in Table 3.1.  
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RNA extraction and RT-qPCR  
RNA was extracted from cells using the RNeasy mini kit (Qiagen, Germantown, 
MD) and DNA was removed by on-column DNase digestion (Qiagen) according to the 
manufacturer’s protocol. One microgram of RNA was used to synthesize cDNA using the 
high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. RT-qPCR analyses were performed using SsoFast EvaGreen 
supermix (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol and GAPDH 
was used as a control. Primer sequences used for qRT-PCR are listed in Table 3.2.  
 
SA-β-gal assay 
Huh7, Hep3B, and SNU-475 cells were seeded onto 12-well plates, senescence-
associated β-galactosidase (SA-β-gal) staining was performed at pH = 6.0 and positively 
stained cells were quantified as previously described (163). 
 
Immunoblot Analysis  
Cells were washed twice with ice-cold PBS and harvested in RIPA buffer (Boston 
Bioproducts, Ashland MA) supplemented with protease (Roche, Indianapolis, IN) and 
phosphatase inhibitor cocktails (Thermo Fisher Scientific). The concentration of protein 
was measured using the BCA assay (Thermo Fisher Scientific). For each sample, 25 µg 
of protein was loaded onto an SDS-PAGE gel. The following antibodies were used to 
probe against: TRRAP (#3967; Cell Signaling Technology, Danvers, MA), KAT2A 
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(#3305; Cell Signaling Technology), KAT5 (sc-166323; Santa-Cruz Biotechnology, 
Dallas, TX), GAPDH (MAB374; Millipore Sigma, Burlington, MA), Hsp90 (#610419; 
BD Bioscience, San Jose, CA), p21 (#2947; Cell Signaling Technology), and p53 (sc-
126; Santa-Cruz Biotechnology). Bands were visualized with an immunofluorescent 
secondary antibody (LICOR) using the Odyssey Imaging system.   
 
Flow cytometry analyses  
For cell cycle analysis, Huh7 and SNU-475 cells were pulsed with 30 µg/mL 5-
Bromo-2´-Deoxyuridine (BrdU, Thermo Fisher Scientific) for 1 hour at 37 C. Cells 
were then trypsinized and fixed with 70% ethanol, permeabilized with 0.3% Triton-X 100 
and incubated with a BrdU-FITC conjugated antibody (Thermo Fisher Scientific). Cells 
were stained with 50 ng/mL propidium iodide (Thermo Fisher Scientific), 10 g/mL 
RNase A (Thermo Fisher Scientific), and incubated for 30 minutes at 37oC. For H2AX 
analysis, cells were fixed in 70% ethanol, permeabilized with 0.3% Triton-X100 and 
blocked in 0.8% BSA. Cells were then incubated with an anti-γH2A.X antibody (#9718; 
Cell Signaling Technology), which was detected using a mouse-FITC IgG. Cells were 
also stained with propidium iodide as described above to identify 2N and >2N 
populations. For each sample, at least 40,000 cells were analyzed using the MACSQuant 
VYB Flow cytometer (MACS Miltenyi Biotec, Auburn, CA). All data were analyzed by 
FlowJo 10.0 software.   
 
Statistics 
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Statistical analysis was performed using GraphPad Prism software and data were 
presented as means  standard deviation. Student’s t-test was used to determine P-values 
unless indicated otherwise. P-values of <0.05 were considered to be statistically 
significant. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Loss of TRRAP induces senescence in HCC cells.  
A) 10x Phase images of TRRAP depleted HUH7 and SNU-475 cells depicting senescent 
cells (red arrowhead). B) SA--gal staining of TRRAP depleted HUH7, SNU-475 and 
HEP3B cells with corresponding mutations in TP53 and RB. C) Quantification of SA--
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gal shown in B. Data was presented as mean ± SD; p-values were calculated by 
comparing to sgNT, *p < 0.05, **p < 0.01, ***p < 0.001 (student’s t test).     
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Figure 16. Loss of TRRAP results in elevation of senescence markers in HCC cells.  
P21 protein expression in (A) Huh7, (B) Hep3B, and (C) SNU-475 cells infected with 
non-target (sgNT) and 3 individual TRRAP sgRNAs (sgTRRAP) and mRNA levels of 
p15, p16, and p21 in the corresponding TRRAP depleted cells lines as measured by qRT-
PCR and normalized to sgNT cells. GAPDH was used as a loading control for western 
blots. Data was presented as mean ± SD; p-values were calculated by comparing to sgNT, 
*p < 0.05, **p < 0.01, ***p < 0.001 (student’s t test). 
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Figure 17. Loss of KAT5 and not KAT2A results in senescence in HCC cells.  
A) SA--gal staining of KAT2A and KAT5 depleted HUH7 and SNU-475 cells. B) 
Quantification of SA--gal shown in A. C) P21 protein expression in HUH7 and D) 
SNU-475 cells infected with sgNT and sgKAT2A and sgKAT5 and mRNA levels of p15, 
p16, and p21 in the corresponding cells lines as measured by qRT-PCR and normalized 
to sgNT cells. GAPDH was used as a loading control. Data was presented as mean ± SD; 
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p-values were calculated by comparing to sgNT, *p < 0.05, **p < 0.01, ***p < 0.001 
(student’s t test).    
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Figure 18. TRRAP/KAT5 loss induced senescence is independent of canonical 
mediators of senescence. 
A) Protein expression of P21 and Phospho Rb in HUH7 cells infected with three 
individual TRRAP sgRNAs. GAPDH was used as a loading control. B) mRNA levels of 
TERT in HUH7 cells infected with sgNT, sgTRRAP, sgKAT2A and sgKAT5. C) DAPI 
staining of HUH7 cells infected with sgNT and sgTRRAP. D) Flow cytometry analysis of 
DNA damage in Huh7 cells using γH2A.X in the total cell population, 2N and >2N 
populations. DNA content was determined using PI staining.     
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Figure 19. TRRAP and KAT5 depletion induced senescence is independent of P21. 
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A) Schematic illustrating generation of p21 and TRRAP/KAT5 double knockout cells 
using CRISPR. B) Western blot analysis of TRRAP, KAT5 and p21 levels in Huh7 and 
SNU-475 cells infected with the indicated sgRNAs. HSP90 and GAPDH were used as a 
loading control. C) Colony formation and SA-β-gal staining of Huh7 cells infected with 
the indicated sgRNAs. NS = not significant (student’s t test). D) Colony formation and 
SA-β-gal staining of SNU-475 cells infected with the indicated sgRNAs. NS = not 
significant (student’s t test).    
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Figure 20. TRRAP and KAT5 depletion induced senescence is independent of P53. 
A) Western blot analysis of TRRAP, KAT5 and P53 levels in Huh7 cells infected with 
the indicated sgRNAs. GAPDH was used as a loading control.B) SA-β-gal staining of 
Huh7 cells infected with the indicated sgRNAs.  
  
P53 
sgNT sgP53 
P21 
GAPDH 
sgNT sgTRRAP sgKAT5 
sgNT sgP53 
sgNT sgTRRAP sgKAT5 
A 
B 
 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. TRRAP and KAT5 depletion induces senescence during G2/M. 
A) Cell cycle analysis of Huh7 cells and B) SNU-475 cells infected with the indicated 
sgRNAs by BrdU and PI staining. Representative data (left) and quantification (right) are 
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shown here. Data was presented as mean ± SD; p-values were calculated by comparing to 
non-targeting control, *p < 0.05, **p < 0.01, ***p < 0.001 (student’s t test).  
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Figure 22. Loss of TOP2A induces senescence in HCC cells. 
A) SA-β-gal staining of Huh7 and SNU-475 cells infected with sgTOP2A with 
quantification of positive cells.  B) P21 protein expression in Huh7 cells infected with the 
indicated sgRNAs and mRNA levels of senescence markers p15, p16, and p21 in Huh7 
cells infected with sgTOP2A. GAPDH was used as a loading control. C) P21 protein 
expression in SNU-475 cells infected with sgNT and sgKAT2A and sgKAT5 and mRNA 
levels of p15, p16, and p21 in the corresponding cells lines as measured by qRT-PCR and 
normalized to sgNT cells. HSP90 was used as a loading control. Data was presented as 
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mean ± SD; p-values were calculated by comparing to non-targeting control, *p < 0.05, 
**p < 0.01, ***p < 0.001 (student’s t test). 
 
Figure 23. Loss of TOP2A arrests cells in G2/M independent of DNA damage. 
A) Flow cytometry analysis of DNA damage in Huh7 cells using γH2A.X in the total cell 
population, 2N and >2N populations after infection with the indicated sgRNAs. DNA 
content was determined using PI staining. B) Cell cycle analysis of Huh7 cells infected 
with the indicated sgRNAs. Representative data (left) and quantification (right) are 
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shown here. C) Cell cycle analysis of SNU-475 cells infected with the indicated sgRNAs. 
Representative 
data (left) and 
quantification 
(right) are 
shown here.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 List of sgRNAs sequences used in Chapter III.  
  
sgRNA name Sequence (5'-3') 
sgTRRAP.1 ACTCCTGATACAAGAGATCG 
sgTRRAP.2  CTTGATCCGCCACTATACGA 
sgTRRAP.3 CCACTGGGGATCGTTCAGTG 
sgKAT2A.1 GCTGCTGGAAAAGTTCCGAG 
sgKAT2A.2 TCACCATGCCACCCTCAGAG 
sgKAT5.1 GATTGATGGACGTAAGAACA 
sgKAT5.2 ACCAGGCTGCCAGTCATGCG 
sgp21 GTCACCGAGACACCACTGGA 
sgTOP2A.1 TGTACGCTTATCCTGACTGA 
sgTOP2A.2 GATGCTGCTATCAGCCTGGT 
sgP53 AGCGCTGCTCAGATAGCGA 
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Primer name Sequence (5'-3') 
p15-F AAGCTGAGCCCAGGTCTCCTA 
p15-R CCACCGTTGGCCGTAAACT 
p16-F CCCAACGCACCGAATAGTTA 
p16-R ACCAGCGTGTCCAGGAAG 
p21-F CAGCAGAGGAAGACCATGTG 
p21-R GAGGCACAAGGGTACAAGACA 
GAPDH-F CTGGGCTACACTGAGCACC 
GAPDH-R AAGTGGTCGTTGAGGGCAATG 
 
Table 9 Primers used for qRT-PCR in Chapter III. 
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CHAPTER IV 
Discussion 
 
Overview of key findings and model 
 Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer with 
few effective treatments as the underlying mechanisms that drive HCC pathogenesis 
remain poorly characterized. Identifying genes and pathways essential for HCC cell 
growth will aid the development of new targeted therapies for HCC. Using a kinome 
CRISPR screen in three human HCC cell lines, we identified transformation/transcription 
domain-associated protein (TRRAP) as an essential gene for HCC cell proliferation.  
TRRAP has been implicated in oncogenic transformation, but how it functions in 
cancer cell proliferation is not established. Here, we show that depletion of TRRAP or its 
co-factor KAT5, inhibits HCC cell growth in vitro and in-vivo as tumor xenografts. 
Furthermore, using a genetically engineered mouse model, we demonstrated that TRRAP 
loss is correlated with loss of HCC tumor formation in vivo. Interestingly, we identify 
that loss of TRRAP results in loss of KAT5 protein while mRNA levels remain stable. 
Mechanistically we conclude that loss of KAT5 protein is not due to proteasome or 
lysosome mediated degradation suggesting that the KAT5 transcript is not being 
translated in the absence of TRRAP.       
Integrating cancer genomics analyses using patient data and RNA-sequencing 
identified mitotic genes as key TRRAP/KAT5 targets in HCC. In line with this, cell cycle 
analyses revealed that TRRAP- and KAT5-depleted cells are arrested at G2/M phase. We 
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identify that TRRAP and KAT5 depletion results in induction of p53- and p21-
independent senescence in the absence of DNA damage. Finally we identify TOP2A as a 
mitotic target gene of TRRAP/KAT5. Furthermore, depletion of TOP2A was sufficient to 
recapitulate the senescent phenotype of TRRAP/KAT5 knockdown.  
Our results uncover a role for TRRAP/KAT5 in promoting HCC cell proliferation 
via activation of mitotic genes. Furthermore, the work in this thesis suggests that 
targeting the TRRAP/KAT5 complex is a potential therapeutic strategy for HCC (Figure 
4.1). 
 
The role of TRRAP in HCC development 
The work in this thesis is one of the first to report a role for TRRAP in HCC. As 
an essential component of HAT cofactor complexes, TRRAP can exert its effects on the 
cell through transcriptional regulation of key programs. One of the first studies to 
characterize TRRAP driven transcriptional programs through microarrays demonstrated 
that Trrap loss in mouse embryonic fibroblasts (MEFs) resulted in decreased expression 
of programs related to transcription, protein turnover, cytoskeleton and cellular adhesion 
and cell cycle progression (130). ChIP based validation of some of these targets, like 
Cyclin A, attributed the decrease in expression to decreased histone acetylation. 
Interestingly after Trrap loss, MEFs had increased expression of programs related to 
protein turnover and metabolism suggesting that TRRAP binding to these loci may also 
play a repressive role. The authors did not directly address the significance of TRRAP 
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repressed genes in this study. Moreover, later studies also demonstrated that members of 
the MYST family, like KAT5, can also repress gene expression (146). 
TRRAP’s regulation of cell cycle genes warranted further investigation as this 
was the largest subset of genes that were depleted upon TRRAP depletion. A study 
demonstrated that Trrap loss led to chromosome missegregation and failure to induce 
expression of the checkpoint proteins Mad1 and Mad2 secondary to loss of Kat5 
mediated epigenetic acetylation in MEFs (129). However, in that study, Trrap-deficient 
MEFs entered mitosis and initiated mitotic exit at similar kinetics as Trrap-containing 
MEFs and Kat5 protein levels were similar between Trrap-deficient and Trrap-
containing cells suggesting that TRRAP targets in MEFs may differ from HCC.  
Genome wide unbiased characterization of TRRAP programs in malignancies is 
currently lacking in the field. TRRAP has been implicated in multiple malignancies such 
as GBM and ovarian cancers in which it can drive differentiation of tumor initiating stem 
cells (194, 264). The work in this thesis is one of the first to characterize TRRAP 
regulated programs in HCC. Like the microarray study done by Herceg et al. (130), we 
identified similar transcriptional programs that were depleted upon TRRAP loss in HCC 
cells such as those responsible for cell cycle progression, chromosome segregation and 
cytokinesis. However, further transcriptome analysis of TRRAP depleted HCC cells also 
identified a subset of genes responsible for chromosomal instability. Previous studies 
have demonstrated that YAP1 and FOXM1 can drive expression of a chromosomal 
instability signature in HCC that correlates with survival in patients (206). Work in this 
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thesis suggests that TRRAP and KAT5 can also drive expression of a subset of the genes 
in this signature in both HCC cell lines and patient HCC samples.  
Moreover, we also identified metabolism and extracellular matrix transcriptional 
signatures that were upregulated upon TRRAP loss. Studies investigating the direct 
relationship between TRRAP and cellular metabolism are limited. Furthermore given that 
TRRAP can bind and stabilize the transcription factor MYC, one of the major regulators 
of cellular metabolism (265), it would not be surprising that TRRAP can influence 
metabolic pathways. Interestingly, in this thesis we identify a subset of metabolism 
related genes normally inhibited by TRRAP that are liver specific. Furthermore, 
increased expression of these genes correlated with more favorable prognosis in patients. 
However future studies need to validate the consequences of TRRAP regulated 
metabolism genes in HCC models. Taken together, transcriptional programs regulated by 
TRRAP between MEFs and HCC is relatively conserved.   
From the work in this thesis, we can begin to speculate the role of the 
TRRAP/KAT5 as an oncogene in HCC from its epigenetic functions. We demonstrate 
that TRRAP drives expression of a genetic signature responsible for mitotic progression. 
Overall aberrant mitotic activation and G2/M checkpoint dysregulation can result in 
chromosomal instability (37). Since chromosomal instability is a mediator of 
transformation in HCC (6) and hepatocytes suppress their normal functions as they 
transform into HCC (207), we can suggest that TRRAP overexpression can drive 
transformation of hepatocytes by inducing expression of this chromosomal instability 
signature thereby promoting aberrant mitosis and repressing genes required for normal 
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hepatocyte functions, such as those required for bile acid metabolism. However future 
studies examining the effect of TRRAP overexpression in hepatocytes are needed in 
order to test this hypothesis.  
TRRAP is a large scaffold protein and serves as a binding partner for the HATs 
KAT5 and KAT2A. However TRRAP can also bind non HAT proteins such as MYC, 
ATM, E2F1 and P53 through its FATC and HEAT domains (118). Deletion of these 
domains in yeast does have deleterious effects on cell viability suggesting that TRRAP’s 
interactions with non-HAT proteins and non-histone targets is also important for its 
function.  
The MYC protein consists of six regions, termed MYC homology boxes (MB). 
Early studies demonstrated that TRRAP’s interaction with MYC and E2F is required for 
transformation by both proteins (117, 144). Furthermore, a more recent study 
demonstrated that MBII, specifically, mediates interaction with TRRAP and is required 
for transformation (193). Moreover loss of TRRAP in hematopoietic stem cells led to a 
decrease in MYC protein levels indicating that TRRAP stabilized MYC in this cell 
population (266). In a mouse model of HCC, MYC depletion led to cellular 
differentiation (267). In this study the authors demonstrated that the surviving cells 
showed stem cell properties and had differentiated into normal hepatocytes. The potential 
MYC-TRRAP interaction is another avenue via which MYC can be drugged. However, 
future studies are required to validate, firstly, whether this interaction in HCC patient 
samples and HCC models exist and, secondly, the consequences of this interaction.  
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Studies in lymphoma models demonstrate that TRRAP can bind mutant P53 
through its N-terminal HEAT domains. Silencing TRRAP in these models reduces 
protein pools of mutant P53 via MDM2 mediated degradation. This suggests that TRRAP 
binds p53 in order to shield it from degradation machinery (195). In this thesis we also 
identify that loss of TRRAP results in decreased expression of P53 in mutant P53 HCC 
cell lines. Taken together the data suggests that TRRAP is also protecting cellular pools 
of mutant P53 from degradation. However, this hypothesis would need to be tested in 
future studies comparing the effects of TRRAP loss on P53 protein levels in WT and 
mutant P53 HCC cell lines.    
Overall, studies investigating TRRAP binding partners in liver biology and HCC 
are limited. One study showed in an HCC cell line that TRRAP can activate nuclear 
receptors such as liver X receptors (LXR), Farnesoid X receptor (FXR), and Peroxisome 
proliferator-activated receptors (PPARs) and regulate lipid metabolism, bile acid 
synthesis and glucose metabolism (268). However, identification of additional TRRAP 
binding partners and validation of previously identified binding partners such as MYC 
and P53 in HCC is required as such studies would identify additional potential 
therapeutic vulnerabilities.  
 
Translational Implications in HCC 
 The purpose of the work in this thesis was to utilize a kinome wide CRISPR 
screen to identify therapeutic vulnerabilities in HCC that were independent of P53 status. 
Our screen identified TRRAP as a potential therapeutic target and our mechanism studies 
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elucidated that TRRAP’s proliferative effect was mediated by KAT5. TRRAP is 
pseudokinase and member of the PI3K family of kinases. Like all PI3K family members, 
TRRAP contains a PI3K domain however, the specific residues mediating phosphate 
transfer are absent (117). Biochemical and functional assays demonstrate that TRRAP 
contains no catalytic activity of its own (125). However, studies have elucidated that 
TRRAP functions as a scaffold protein which binds and stabilizes other proteins. In line 
with this, sequence analyses have demonstrated that TRRAP contains multiple HEAT 
domains that mediate interactions with binding partners such as Myc and P53. TRRAP 
also contains a FATC domain which mediates its interaction with HAT cofactors as well 
as ATM. Due to the fact that TRRAP contains no catalytic activity of its own, there are 
currently no small molecule inhibitors available that can successfully target and inhibit 
TRRAP. However, given the essential functions of TRRAP in driving tumorigenesis 
identified in this thesis for HCC and in other cancers it is important to evaluate the 
potential therapeutic strategies that can be utilized to target this protein. 
 It is important to note that the crystal structure for Tra1, the yeast homolog of 
TRRAP, in both the SAGA complex and NuA4 complex has been solved within the last 3 
years (226, 269, 270). Therefore, it may be possible to utilize this structural information 
to target and disrupt the interaction between TRRAP and KAT5 as a therapeutic strategy. 
Furthermore, advances in siRNA-based therapeutics now enables efficient silencing in 
vivo after one dose (271). In line with this, siRNA based therapies against the MYC 
oncogene and Plk1 are currently in Phase 1 clinical trials for HCC (272). However it 
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would be imperative to assess the effects of TRRAP inhibition in normal hepatocytes to 
gain insight into the potential toxicities associated with “drugging” TRRAP.  
 In addition to identifying TRRAP as a therapeutic target, the work in this thesis 
also suggests that KAT5 depletion can phenocopy TRRAP loss. Moreover, small 
molecules that inhibit KAT5 are currently in development. Anacardic acid and its analogs 
have similar chemical structures to Acetyl CoA and therefore block the acetyl coA 
binding site of KAT5. Indeed, treatment with Anacardic acid inhibited KAT5 dependent 
acetylation and activation of ATM in HeLa cells and also sensitized the cells to radiation 
induced DNA damage (273). Moreover, treatment of HeLa cells with pentamidine, 
another Acetyl CoA mimic, also inhibited KAT5 activity and sensitized cells to radiation 
induced DNA damage (274). However, both these compounds were used at relatively 
high concentrations (>100M) to elicit this response, suggesting that their in-vivo 
efficacies would be low. Furthermore, given that these compounds are Acetyl CoA 
mimics, it is possible they would bind to and inhibit the activity of other HATs such as 
KAT2A and P300 and lead to detrimental off target effects and toxicities.  
 Screening of small molecule inhibitors identified NU9056 as a drug that inhibited 
KAT5 function (275). In vitro studies demonstrated that NU9056 had an IC50 of 2.5M 
and was 16.5, 29 and 50-fold more selective for KAT5 at this concentration than PCAF, 
P300 and KAT2A respectively. Treatment with NU9056 prevented acetylation of both 
histone and non-histone targets. Moreover, functionally, NU9056 treatment induced P21 
expression and apoptosis in prostate cancer cell lines.  
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 More recently, a group took advantage of the crystal structure of KAT5 and 
designed a small molecule, TH1834, which selectively bound the active site of KAT5 
(227). In this study treatment with TH1834 induced apoptosis in MCF-7 cells, a HER2 
negative breast cancer cell line, but did not affect viability of MCF-10 cells, a normal 
breast epithelial cell line. Furthermore, the authors demonstrated that the drug was 
selective for KAT5 as acetylation of the H4K16 residue, a target of the HAT MOF, was 
not impacted (227). However, the authors used a dose of 500uM in all of these studies 
suggesting that the drug may not show efficacy in vivo. Taken together, multiple attempts 
have been made to design small molecules that target the catalytic activity of KAT5. In 
vitro NU9056 and TH1834 demonstrate efficacy in prostate and HER2 negative breast 
cancer cell lines respectively however the efficacy of these compounds in HCCs remains 
to be tested.  
 Other HATs have also been successfully targeted using small molecule inhibitors. 
Of note Curcumin and Garcinol, both of which are p300 inhibitors demonstrated 
therapeutic efficacy in HCC cell lines in vitro (140). Furthermore inhibition of p300 with 
Curcumin induced senescence in SAOS-2 cells, an osteosarcoma cell line (253). KAT6 is 
often amplified in cancers (276) and functions to suppress senescence by repressing the 
p16 locus (277). In line with this, a group designed a small molecule inhibitor against 
KAT6A/B which decreased tumor progression by inducing senescence in a zebrafish 
model of HCC and in a mouse model of lymphoma (278).  
 The work in this thesis also identified that loss of TOP2A induces senescence in 
HCC models. Multiple attempts have been made in HCC patients to inhibit TOP2A using 
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drugs like doxorubicin and etoposide, however none have shown clinical efficacy through 
systemic delivery. However, delivery of Doxorubicin directly to tumors using 
transarterial chemoembolization has shown significant survival benefits in HCC with low 
toxicities (279) suggesting that failure of drugs like doxorubicin and etoposide is due to 
cytotoxicity secondary to off target effects. In line with this, studies have demonstrated 
that the cardiotoxicity commonly associated with Etoposide is due to inhibition of 
TOP2B, as TOP2A is not appreciably expressed in quiescent cells (280). Furthermore, in 
addition to inhibiting TOP2B (281), Doxorubicin has been demonstrated to dysregulate 
ceramide synthesis a mechanism potentially contributes to its toxicity (282).  
 Hence, there is a need to develop small molecule inhibitors that are selective for 
TOP2A. NK314 was one such compound that was developed that was highly selective 
against TOP2A (283). Moreover, in this study, the authors demonstrated that NK314 had 
greater anti-tumor activity and showed less toxicity towards cells that had low levels of 
expression of TOP2A compared to drugs like etoposide and doxorubicin. The antitumor 
effect of NK314 remains to be tested in HCC, however its development serves as 
evidence that designing inhibitors specific to TOP2A can revitalize TOP2A as a viable 
therapeutic target.   
 
Study Caveats 
Using CRISPR based screening and passaging cells for 10 passages we were able 
to identify kinases that were mediators of proliferations in HCC. However, our screen 
also identified key kinases that are responsible for proliferation in normal cells- these 
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include BUB1, AURKA, and PGK1. Thus, one caveat to this study was the fact that the 
screen also identified kinases that are responsible for proliferation in normal cells. Future 
studies can circumvent this and allow for stratification of kinases that are cancer specific 
by performing this screen in tandem with a normal immortalized hepatocyte cell line such 
as THLE-2. Furthermore, the hits of our screen are kinases that are implicated in 
proliferation, future studies can screen for kinases that can aid in other processes which 
can be therapeutically targeted including metabolism and autophagy.  
Another caveat to the study arises from the nature of generating CRISPR 
knockouts. Due to the antiproliferative nature of the phenotype we were unable to 
generate knockouts that arise from a single clone. After the generation of a DSB at the 
desired genomic loci, the cells undergo NHEJ based DNA repair. The result is the 
generation of an indel that could be ±1, ±2 or ±3 nucleotides (89). Consequently, the 
knockouts generated in this study were comprised of a genetically polyclonal population 
with varying indels and, consequently, varying degrees of knockout at the single cell 
level. In line with this, we demonstrated via western blotting that the population as a 
whole had depleted levels of the target protein thereby providing credence to the 
conclusions made in this study. Furthermore, we were successfully able to validate the 
conclusions from our study using two different sgRNAs as well as sh- and siRNA-based 
knockdown therefore suggesting that our senescence phenotypes were due to gene 
specific knockdown. 
 The generation of a doxycycline inducible shRNA model of TRRAP loss would 
aid in circumventing this caveat as we could perform more mechanistic studies and 
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validate the conclusions from the current study using a monoclonal population. 
Alternatively, the relationship between TRRAP and KAT5 levels and TOP2A levels can 
be performed at the single cell level in our polyclonal population using 
immunofluorescence to further validate these relationships.  
Additionally, the data suggesting that TRRAP loss induced senescence is 
mediated by KAT5 and TOP2A is correlative as we were unable to overexpress KAT5 
and TOP2A in TRRAP depleted cells to determine if this would rescue TRRAP induced 
senescence. Given that TRRAP and KAT5 regulates a network of genes responsible for 
mitotic progression I would expect that overexpression of a single gene would not rescue 
the senescence phenotype, however this would need to be investigated by future 
experiments. 
 
Outcomes of cell cycle arrest 
As discussed earlier, cell cycle progression can be impeded due to a variety of 
toxic insults such as withdrawal of mitogenic factors, DNA damage, nucleotide 
deprivation and chemotherapeutics. However, the consequences after arrest are variable 
from cell to cell. The two major outcomes are senescence or cell death but how a cell 
decides to senesce or die remains relatively unknown. The emerging molecular pathways 
implicated in this fate decision are the P53-P21 axis, signaling through the PTEN-AKT-
mTOR pathway and the degree of molecular damage (284). 
The P53-P21 pathway is considered to control the balance between pro-apoptotic 
and pro-senescent pathways. p53 is a transcription factor and can activate hundreds of 
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genes in response to a large number of stress signals, including those that regulate cell 
cycle progression. An early study examined the balance of the p53 and p21 axis in 
regulating the decision to senesce or undergo apoptosis (285). In this previous study, the 
authors treated IMR-90 fibroblasts with H2O2 and noted a fraction of the cells had 
detached. Analysis of the detached cells revealed caspase-3 activation and typical 
morphological changes associated with apoptosis whereas the adherent cells were growth 
arrested during G1 and had elevated expression of p21. Interestingly, the authors 
observed greater induction of p53 in the detached cells compared to the adherent cells. 
Furthermore, depletion of p53 in this study decreased the activation of caspase-3 and 
decreased the proportion of apoptotic cells suggesting that expression levels of p53 can 
control the decision to undergo senescence or apoptosis (285). Recently, studies 
demonstrated that the temporal dynamics of P53 expression can influence cell fate 
decisions. IR induces P53 protein levels to appear in pulses and thereby allows for repair 
of damage without interruption in cell cycle progression. However, studies demonstrated 
that if this “pulse-like” expression pattern is pharmacologically altered such that P53 
protein levels are sustained, the cells are unable to progress through the cell cycle and 
will senesce (286). Other studies examining cell fate at the single cell level demonstrate 
that the decision to die or arrest is not determined by a fixed threshold of p53 expression 
but rather depends on the time and levels of P53 as the threshold level of P53 to induce 
apoptosis increases with time due to induction of anti-apoptotic factors (287).  
 In addition to expression level, post translation acetylation can also control P53’s 
ability to regulate cell fate decisions (284). P53 has two key residues that can be 
 129 
acetylated, K120 and K164. Studies have shown that K120 is acetylated by KAT5 
whereas K164 is acetylated by P300 (237, 288). K117 is the mouse analog of K120 in 
humans. Studies demonstrated that cells in mice with a K117R mutation in P53, could not 
initiate apoptosis in response to DNA damage as they were not able to induce expression 
of puma and initiate caspase activation (289). However, in this study, cells from these 
mutant mice were able to undergo senescence to the same extent as WT mice in response 
to doxorubicin suggesting that acetylation of K117 is required to initiate apoptosis. 
However MEFs isolated from mice harboring mutations in both acetylation residues were 
unable to senesce or undergo apoptosis in response to toxic stimuli (289) suggesting that 
acetylation of the K164 residue by P300, was responsible for activation of a senescence 
program. 
Another study demonstrated that quaternary structure of P53 was important for 
the ability of P53 to activate apoptotic programs. Mutating a residue within P53 that was 
responsible for P53 multimerization and cooperativity of DNA binding resulted in failure 
to initiate pro-apoptotic programs. However, expression of other P53 target genes in these 
mutants, such as those responsible for senescence remained unchanged, and the cells 
retained their ability senesce in response to toxic stimuli (290). 
p21 is a major target of p53 and is responsible for initiating a pro-senescence 
program. In vitro studies demonstrated that treatment with low dose doxorubicin 
triggered senescence associated with p21 induction whereas high dose doxorubicin 
triggered apoptosis in the absence of p21 induction in HCC, breast and colorectal cancer 
models (284). Furthermore, ectopic expression of p21 was sufficient to induce 
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senescence in cancer cell lines with WT p53 and those with mutations and deletions in 
P53 (291, 292). Mechanistically, p21 must be localized in the nucleus in order to mediate 
its cell cycle arrest functions. In line with this, studies have demonstrated that AKT 
mediated phosphorylation of p21 induces retention of p21 in the cytoplasm and allows 
for cellular proliferation (293).  
Traditionally senescence studies involved analysis of polyclonal populations of 
cells. These studies established that p21 expression was induced during the process of 
senescence induction (i.e. 2-3 days before cells exhibited the classical flattened 
morphology and stained positive for SA--Gal) and that “high levels” of P21 were 
required for induction of senescence as p21 knockout cells were unable to undergo 
senescence (294). Longitudinal analysis of p21 expression at the single cell resolution 
however demonstrated that expression of p21 immediately after senescence inducing 
treatment influenced cell fate (295). In this recent study, the authors demonstrated that 
expression of p21 immediately after treatment withdrawal (within 5 hours) led to 
proliferation whereas p21 expression 23-36 hours after treatment withdrawal resulted in 
senescence. Furthermore the authors demonstrated that the cells fated for proliferation 
had a transient “pulse” of p21 expression during drug treatment (295). Interestingly, these 
studies were conducted in WT P53 cells. The mechanisms that regulate these unique 
dynamics of P21 expression remain unknown and require investigation in future studies.        
The effects and targets of p53 have been well established in regulating the cells 
decision to undergo apoptosis or senescence. PTEN is a tumor suppressor gene that 
suppress activity of AKT and mTOR, two kinases implicated in cell cycle progression. 
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Studies have demonstrated that loss of PTEN induces senescence in certain mouse 
models of cancer and human cancer cell lines, including HCC (296). Interestingly, 
studies have demonstrated that PTEN can also regulate the cell’s decision to undergo 
apoptosis or senescence. Radiation induced DNA damage of glioma cells that were WT 
PTEN resulted in cellular senescence that was mediated by the P53-P21 axis whereas 
DNA damage of PTEN null cells underwent apoptosis (247).  In line with PTEN 
suppression of AKT, mTOR inhibition prevents senescence in response DNA damage 
(297).  
Finally, studies have implicated DNA damage as a factor controlling the cells 
decision to undergo apoptosis or senescence. Although the exact mechanism of how 
DNA damage can result in senescence or apoptosis is unclear. Leaders in the field 
speculate that there is a “threshold” of DNA damage that once reached tips the balance 
between apoptosis and senescence (298). However experimental evidence of this 
threshold is lacking. Moreover, a recent study demonstrated that the decision to senesce 
is not due to the amount of DNA damage but rather the cell’s ability to discern between 
repairable and irreparable damage (262). In this previous study, the authors demonstrated 
that “difficult to repair breaks” were marked by dual RPA and 53BP1 positive foci. 
Moreover cells that contained dual positive foci were the ones that senesced. This work 
was done in immortalized fibroblasts with functional WT P53 and a conserved P53-P21 
axis. Whether the same decision-making criteria holds true in cancer cells with 
aberrations in P53 requires further investigation.   
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The work in this thesis demonstrates that loss of TRRAP/KAT5 induces 
senescence in HCC by downregulation of genes responsible for mitotic progression. 
Interestingly the work on this thesis was done in mutant and p53 null HCC cell lines 
suggesting that the decision to senesce after TRRAP/KAT5 depletion was independent of 
p53. p53 independent mechanisms of cell fate remain largely unknown. One study 
demonstrated that in response to DNA damage NF-κB, activated by ATM and NEMO, 
can drive cellular programs that either activate a pro-inflammatory signature containing 
IL-8 or activates FADD mediated caspase 8 activation (299). In this study the authors 
speculated that the IL-8 proinflammatory signature was similar to the SASP however 
they did not directly test this hypothesis. Furthermore other studies have demonstrated 
that p53 independent induction of p21 expression is mediated by ATM as ATM signaling 
can directly induce p21 expression (300). Taken together the data suggests that 
TRRAP/KAT5 induced senescence may be mediated via ATM and NF-κB, however 
future studies are required to test this hypothesis.   
 
Senescence during G2/M 
 Cell cycle analysis revealed that classical inducers of senescence such as RAS and 
telomere erosion arrested cells during G1 (151). Mechanistically, this was attributed to 
increased expression of P16 and P21 which inhibited phosphorylation of Rb thus 
blocking progression into S phase. Almost 25 years ago studies first described that cells 
could arrest during G2/M in response to DNA damage. The prevailing mechanism in the 
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field suggests that ATM/ATR activates CHK1/2 kinase that inhibits CDC25 phosphatase 
activity thereby inhibiting activation of Cyclin B1 and arresting cells in G2 (258). 
Initial work from the Vogelstein group demonstrated that p21 could maintain 
G2/M arrest. The group demonstrated DNA damage did not induce arrest in p21 
knockout HCT116 cells. Instead the cells underwent aberrant mitosis resulting in 
polyploidy and cell death (301). Later studies elucidated multiple mechanisms for the 
role of p21 in G2/M arrest. One group demonstrated that p21 induced senescence during 
G2 by prematurely activating the APC/C complex which resulted in degradation of 
Cyclin B1 and other drivers of mitosis (302). Other groups suggested that E2F also has 
targets that allow progression through G2/M. In line with this they demonstrated that, in 
addition to during G1, p21 can bind and inhibit Rb phosphorylation during G2 and inhibit 
activation of G2/M related targets of E2F (258).      
 The initial studies utilized DNA damage to induce G2/M arrest. Several recent 
studies have confirmed the mechanistic findings from above but have also identified new 
triggers for G2/M senescence in addition to DNA damage. One group identified that a 
population of cells that undergo replicative senescence can also arrest during G2. Notably 
these cells had elevated levels of Cyclin E and Cyclin D, while Cyclin B was 
undetectable (303). In line with replicative senescence occurring during G2, another 
study found that telomerase negative cells with eroded telomeres senesced during G2 
(304). Taken together the studies suggest that telomere attrition will activate the G2/M 
checkpoint and trigger senescence. Finally, another group demonstrated that loss of 
chromatin acetylation reduced accessibility to the chromatin during replication and 
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induced G2/M arrest (253). Additional studies have identified other inducers of G2/M 
arrest with drugs such as Curcumin and Naphthylamide derivatives. Furthermore arrest 
was correlated with activation of the ATM/ATR network (258). 
In addition to activation of ATM/ATR studies have demonstrated that Cyclin B 
dynamics can influence G2 arrest. Work by the Medema group demonstrated that the 
decision to arrest during G2 is dictated by the timing of Cyclin B1 translocation into the 
nucleus (261). In this study, the authors fluorescently tagged Cyclin B1 at its native locus 
and visualized translocation dynamics after radiation induced DNA damaged. They 
concluded premature translocation into the nucleus of Cyclin B1 resulted in arrest and 
senescence. Interestingly depleting P53 and P21 via siRNAs reduced translocation of 
Cyclin B1 suggesting that the P53-P21 axis was required for Cyclin B1 translocation 
mediated cell cycle arrest. Furthermore, immunoprecipitation experiments in this study 
confirmed that P21 can bind to Cyclin B1.  
In this thesis we demonstrate G2/M arrest that is not associated with increased 
levels of H2A.X and DNA damage. The arrest and senescence during G2/M is most 
likely due to failure to activate genes required for mitotic progression by the 
TRRAP/KAT5 complex. In support of this, previous studies examining the effects of 
TRRAP depletion in MEFs demonstrate that re-expression of the mitotic assembly 
checkpoint genes, Mad1 and Mad2, rescues the cell cycle arrest induced after TRRAP 
depletion (129). Furthermore, the failure to induce expression of genes responsible for 
mitotic progression suggest that the cells are undergoing a form of replication stress. 
Previous studies have demonstrated that ATR activation can occur and induce senescence 
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without DSBs (305). Therefore, we predict that senescence induced after TRRAP/KAT5 
depletion is mediated by ATR activation, however this hypothesis needs to be tested in 
future studies.    
p21 Independent Senescence 
 The molecular pathways that are required for senescence are currently debated in 
the field. When they were first identified, studies suggested that senescence due to 
replication stress, SAHF, the SASP and introduction of oncogenes required components 
of the Rb pathway such as P53, P21 and P16 (155). However, as discussed earlier, studies 
are now demonstrating that signaling in other pathways such as AKT/mTOR, NFB and 
ATM/ATR can converge on the targets of P53, P21 and P16 in order to mediate the 
senescence responses. Taken together with the data from this thesis, this suggests that the 
P53-P21 may not be required for some forms of senescence.  
As discussed earlier, multiple groups have reported p53 independent senescence. 
However, there are few studies demonstrating p21 independent senescence. P300 HAT 
inhibition resulted in p53/p21 independent senescence (253). P300 HAT inhibition 
indeed resulted in induction of p21 however knockdown of p21 and p53 with shRNA did 
not rescue senescence. In order to explain this, the authors suggested that P21 was likely 
inactive. Analysis of P21 localization in this study via immunofluorescence and 
validation via fractionation of nuclear vs cytoplasmic components revealed that although 
P21 was increased after P300 inhibition it was localized in the cytoplasm as opposed to 
the nucleus (253). Similar to the findings with the previous study, in TRRAP/KAT5 
depleted cells we observed induction of p21 expression, yet TRRAP/KAT5 depletion in 
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p21 knockout cells also resulted in senescence. This suggests that p21 is not active in 
TRRAP/KAT5 depleted cells. Therefore, future experiments are required to investigate 
localization of P21 in TRRAP/KAT5 knockout cells.  
The major unanswered question that arises from the studies in this thesis is: What 
is the driving force of senescence in TRRAP/KAT5 depleted cells? There are many 
hypotheses that I have outlined in this thesis. I demonstrated that loss of TRRAP results 
in decreased expression of genes required for mitotic progression in HCC and others have 
demonstrated that re-expressing mitotic activator checkpoint genes in TRRAP depleted 
MEFs restores cell cycle progression (129). Therefore, G2/M arrest is likely due to ATR-
induced replication stress incurred via failure to progress into/through mitosis. Studies 
examining localization of Cyclin B would also aid in validating this hypothesis. The next 
question is why cells are senescing independent of the p53-p21 axis and Rb. One group 
reported that OIS via RAS overexpression in human mammary epithelial cells was 
independent of the p53-p21 axis and DNA damage proteins (306). In this previous study 
they reported that senescence required the TGF-β receptor, however the authors did not 
speculate on the role of TGF-β in mediating their senescence response. As mentioned 
earlier, senescent cells also secrete a collection of pro-inflammatory cytokines and 
chemokines, referred to as the SASP. Given that part of the inflammatory cytokine milieu 
associated with the SASP is TGF- β, I would hypothesize that TRRAP/KAT5 depleted 
cells senesce due to activation of the SASP. Studies have previously demonstrated that 
pharmacological inhibition of ATR can attenuate the SASP in RAS induced senescence 
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(307). Therefore, I speculate that SASP genes are activated due to cross talk between 
ATR and NFB. However future studies are required to test these hypotheses.     
  
Senescence as a therapeutic strategy for cancer 
Senescent cells remain viable, but their cellular state is distinct from their 
proliferating counterparts. The cells are characterized by the absence of proliferative 
markers, the presence of CDKIs, SA--gal staining and the presence of SAHF. More 
recently, the SASP has also been implicated as a characteristic of senescent cells. The 
SASP is one of the most profound features of senescence as it facilitates immune-
surveillance and clearance of senescent cells by recruiting and activating distinct cells 
from the innate immune system such as macrophages and NK cells (183).  
Consequently, multiple studies have demonstrated that inducing senescence can 
have an anti-tumor effect in vivo in multiple tumor models such as HCC, NSCLC, 
Colorectal Cancers, and multiple hematological malignancies (151). The cell cycle arrest 
associated with senescence can dramatically reduce cellular growth and proliferation. 
Furthermore, the paracrine effects of the SASP can not only induce senescence in 
surrounding cells but also recruit immune cells to clear the senescent cells.  
The work in this thesis suggests that TRRAP/KAT5 loss induced senescence in 
HCC cells inhibits tumor growth in vivo as subcutaneous xenografts. Furthermore 
TRRAP loss in hepatocytes in vivo via CRISPR mediated editing inhibits tumor 
initiation. The failure to initiate tumorigenesis is correlated with the presence of immune 
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foci that stain negative for CD4 and positive for F480. Clinically, oncological 
therapeutics can result in stable disease, i.e. tumors no longer proliferate, or regression, 
i.e. tumors decrease in size. The in vivo studies data suggest that TRRAP loss induced 
senescence results in decreased proliferation of the cells but also induces the SASP in 
vivo to aid in clearance of the senescent cells. However further experiments are required 
to definitively conclude that can induce tumor regression in vivo. These experiments 
include generating a doxycycline inducible model of TRRAP loss in-vivo to monitor 
potential tumor regression in both WT mice and immunodeficient mice. Identifying 
tumor regression in this model would definitively conclude that loss of TRRAP can not 
only halt tumorigenesis but can also promote tumor regression and clearance. 
However, there are studies that demonstrate situations in which senescent cells are 
not cleared as they have limited immune cell recruitment. Given that senescent cells 
themselves have altered physiology compared to their non-senescent counterparts, many 
of these changes can be targeted for therapeutic benefit especially in senescence models 
that do not elicit a strong SASP response. Work in Clemens Schmitt’s group 
demonstrated that Adriamycin- or Doxorubicin-induced senescence in a Myc lymphoma 
model does not induce a strong SASP response (308). In this study, the authors 
demonstrated that senescent cells exhibited endoplasmic reticulum stress, an unfolded 
protein response (UPR), increased ubiquitination and a shift in glucose metabolism from 
glycolysis to oxidative phosphorylation. In line with this, treatment of Myc-driven 
lymphomas with a senescence inducing agent and an inhibitor of glucose utilization or 
autophagy, led to caspase-12 and caspase 3 mediated apoptosis. These findings unveiled 
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that the cellular changes associated with senescence can be targeted to induce a synthetic 
lethal phenotype.  
 
Escape from Senescence 
Although senescence is a desired therapeutic outcome, the presence of senescent 
cancer cells can have deleterious outcomes due to the fact that the cells remain viable. 
Analysis of single senescent cells via a fluorescence based SA-β-gal assay revealed a 
population of cells that remained at the boundary between “senescent” and “replicating” 
(154). These cellular populations were positive for SA-β-gal and the proliferation marker 
Ki67. The presence of both markers suggested that cells could spontaneously exit from 
senescence (154). Moreover, senescent cells exhibit increased plasticity, express a stem 
cell signature and stem cell phenotype secondary to WNT activation (172, 309). Taken 
together the studies suggested that these “stem-like” senescent cells have the capacity to 
escape however experimental validation of this phenomenon was lacking until recently. 
Studies in Clemens Schmitt’s lab demonstrated that senescent cells can “escape” 
their cell cycle arrest via reorganization of their chromatin. In line with this, when 
senescent cells were allowed to escape senescence via inactivation of Suv39h1, a histone 
methyltransferase that maintains the heterochromatic H3K9me3 residue, or p53 
inactivation they exhibited a much greater tumor initiating capacity than their pre-
senescent counterparts(172, 175, 309).  
More long-term studies in TRRAP depleted HCC cells are required to elucidate 
the consequences of TRRAP loss induced senescence. Given that TRRAP can regulate 
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WNT signaling (118) and also regulate stem cell signatures in cancer models (194), it 
would be interesting to examine whether TRRAP depleted cells can indeed escape 
senescence and if this escape is mediated by stemness and WNT signaling. Furthermore, 
generation of such a model could serve as an endogenous model of escape from 
senescence whereas the work in the Schmitt lab utilized genetic means to induce 
senescence escape.    
 
The Pro-tumorigenic effects of SASP 
Senescence can also have deleterious effects due to the fact that senescent cells 
create a pro-inflammatory environment through the SASP. Initial studies demonstrated 
that when senescent fibroblasts expressing the SASP were co-injected with tumor cells 
into immunodeficient mice, tumor growth increased at a faster rate compared to when 
tumor cells were injected with control non-senescent fibroblasts (184). This study 
provided preliminary evidence that in the absence of immune mediated clearance, the 
SASP can have a pro-tumorigenic effect. Given that HCC arises from pro-inflammatory 
disease such as cirrhosis, obesity, alcoholism and infection with Hepatitis B virus or 
Hepatitis C virus (6) it is important to consider the effects of the pro-inflammatory SASP 
on HCC and overall hepatic health.   
In line with this, mechanistic studies have demonstrated that the pro-inflammatory 
cytokines secreted from senescent cells can promote cell proliferation and lead to 
initiation of HCC in cirrhosis mouse models (310). In this study the authors demonstrated 
that IL-6, a key component of the SASP can activate STAT3, JNK and ERK signaling 
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and ultimately promote HCC tumorigenesis in an obesity mouse model. Similar studies 
have demonstrated that IL-6 secretion from senescent cells can promote breast and 
prostate tumorigenesis and metastasis (311). Furthermore, a more recent study 
demonstrated that IL-1 secretion from senescent hepatic stellate cells can promote HCC 
tumorigenesis in mice after treatment with a chemical carcinogen (312).   
In addition to pro-inflammatory cytokines, SASP components also include growth 
factors like HGF and EGF, proteases like MMP1 and MMP3, and other components like 
collagen and fibronectin (183). All these factors have been demonstrated to promote cell 
proliferation and motility in normal fibroblasts along with cancer cells. Furthermore, 
treatment of cancer models with MMP3 and fibronectin has been demonstrated to 
promote epithelial-mesenchymal transition (EMT) and subsequent carcinogenesis along 
with treatment resistance (313).  
Studies are now beginning to demonstrate that the exact components of the SASP 
vary from model to model and also vary between the reagent that is utilized to induce 
senescence (311). These differences in the SASP secretome can potentially explain this 
variability in response. An in-depth examination of the SASP components secreted in 
response to senescence inducers is integral to ensuring a long-term durable anti-tumor 
response.  
Studies examining the long-term consequences of senescence in liver models and 
senescence in cancer models are lacking. Furthermore, studies demonstrating escape from 
senescence have only recently emerged, but they suggest that initiating senescence alone 
is insufficient for a long-term anti-tumor response. Taken together the studies suggest 
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that in addition to inducing senescence, the cells need to be cleared as this would limit 
escape and would, presumably, also attenuate the proinflammatory effect of the SASP. 
Preliminary data from this study suggests that TRRAP depleted cells can be cleared in 
vivo however the effect of TRRAP loss and clearance of TRRAP depleted cells on the 
tumor microenvironment needs to be studied more rigorously using inducible models of 
TRRAP loss. Furthermore, the consequences of inducing a SASP in the liver long term 
needs to be examined in order to validate senescence inducing agents as a therapeutic 
strategy in the liver.  
  
Concluding Remarks 
 The goal of this thesis was to identify therapeutic targets in HCC that were 
independent of P53 mutations. In line with this we took advantage of advances in genome 
engineering techniques by utilizing the CRISPR Cas9 system to conduct a screen in three 
HCC cell lines with varying P53 mutations. The screen identified a number of potential 
oncogenes, some of which had been previously validated as therapeutic targets in HCC, 
including CDC7, AURKA and PGK1. However, our screen also identified TRRAP as a 
therapeutic target in HCC. Although TRRAP has been implicated in processes like 
cellular differentiation and DNA repair in glioblastoma and melanoma models, this study 
was the first to implicate TRRAP in HCC.  
 The work in this thesis demonstrates that TRRAP and its cofactor KAT5 can 
regulate expression of a genetic signature responsible for mitotic progression in HCC. 
Furthermore, genomic analyses revealed that TRRAP may also play a role in regulating 
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glucose and lipid metabolism in hepatocytes. Furthermore, loss of TRRAP results in 
decreased translation of the KAT5 mRNA thus reducing KAT5 protein levels. Indeed, 
loss of TRRAP and KAT5 results in decreased cell growth in vitro and cell proliferation 
in vivo. Furthermore, depletion of TRRAP in vivo in hepatocytes is correlated with 
decreased tumor initiation in-vivo and the presence of macrophage positive immune foci 
in the liver. TRRAP/KAT5 has been implicated in regulating cell cycle progression in 
various models. However, the work described here demonstrates that the anti-
proliferative effect is due to the induction of senescence during G2/M. Finally, we 
identify TOP2A as a target of TRRAP/KAT5 which, when depleted, also induces 
senescence in HCC cell lines during G2/M.  
 Canonical mediators of senescence include the P53-P21 axis, phosphorylation of 
the Rb protein, SAHF and decreased TERT expression however the work in this thesis 
demonstrates that TRRAP/KAT5 loss is independent of these factors. DNA damage is a 
trigger of senescence and the TRRAP/KAT5 complex is implicated in playing an 
essential role in DNA repair. However, the work in this thesis demonstrates that 
TRRAP/KAT5 loss induced senescence is independent of DNA damage. The work in this 
thesis combined with the literature in the senescence field suggests that senescence may 
be mediated by replication stress induced ATR activation and subsequent SASP 
induction however future studies are required to confirm this. Overall, the work in this 
thesis identifies TRRAP, KAT5 and TOP2A as therapeutic targets in HCC and suggests 
that these targets warrants further drug design efforts.    
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Figure 24. Overall model depicting key findings from this dissertation  
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APPENDIX I 
TRRAP Loss Induces Formation of Micronuclei and DNA Bridges in HCC 
 
Preface 
The data presented in this appendix is unpublished preliminary data. 
 
Background and Significant Results 
 Recently, the Senescence Associated Secretory Phenotype (SASP) has been 
described as a major component of senescent cells. Functionally, the SASP recruits 
immune cells to mediate clearance of senescent cells and also reinforces cell cycle arrest 
in neighboring cells. In line with the latter function, conditioned media of senescent cells 
can indeed induce senescence in dividing cells (314). Analysis of the secreted factors 
from senescent cells using antibody arrays revealed that the SASP included several 
families of factories that categorically were divided into: soluble signaling factors 
(interleukins, chemokines, and growth factors), secreted proteases, and secreted insoluble 
proteins/extracellular matrix (ECM) components (183).  
 Work from previous studies mechanistically established that the SASP 
transcriptional profile was activated by the cGAS-STING cytosolic DNA sensing 
pathway. One of the hallmarks of senescent cells is the presence of micronuclei. 
Senescent cells have fragile membranes due to decreased Lamin B expression (156). This 
nuclear frailty results in ejection of DNA that is bound by histones and often encased in 
Lamin, termed micronuclei (254). The micronuclei bind to and activate the cytosolic 
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receptor, cGAS, and induce expression of SASP genes via activation of the STING 
pathway (255).   
 In line with this, we sought to examine the nuclei of TRRAP, KAT5 and TOP2A 
depleted HUH7 senescent cells. DAPI staining revealed the presence of micronuclei and 
other secondary structures such as DNA bridges (Figure A1.1A) that were in greater 
abundance in TRRAP, KAT5 and TOP2A depleted cells compared to NT cells (Figure 
A1.1B and 1C). Furthermore, analysis of the RNA-seq data from Chapter II revealed that 
SASP genes (previous published in (179) were enriched in TRRAP depleted cells 
compared to NT cells (Figure A1.1D).  
 As seen in the original study by Dou et al (254), we also observe an increase in 
the presence of micronuclei in senescent cells. Furthermore, we also observe an increase 
in SASP gene expression via RNAseq analysis. Our in vivo studies suggest that TRRAP 
depletion is correlated with the presence of F480+ macrophages (Figure 2.6C) suggesting 
that there is immune cell recruitment. Taken together the data suggests that TRRAP 
depleted cells also exhibit the SASP however this requires validation by further 
experiments. Specifically, future studies should validate the expression of SASP genes 
via qPCR or ELISA and should provide conclusive evidence for cGAS-STING activation 
via western blot. Furthermore, studies have demonstrated that overexpression of DNases 
can degrade cytoplasmic micronuclei and attenuate senescence (256). To test whether 
TRRAP loss induced senescence is driven by the presence of micronuclei, future studies 
can overexpress DNase IIa and TREX1 and examine if induction of senescence is 
decreased.  
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 Studies in zebrafish demonstrated that loss of TOP2A impaired hepatocyte 
regeneration due to the failure to resolve DNA bridges during mitosis (315). Given that 
TRRAP/KAT5 can drive TOP2A expression, we also observed formation of DNA 
bridges in TRRAP, KAT5 and TOP2A depleted cells. The study by Dou et al 
demonstrated that micronuclei were ejected directly from nuclei (254). However live cell 
imaging studies of HeLa cells after replication stress demonstrated that an unresolved 
DNA bridge can also be ejected as micronuclei (316, 317). Future studies can utilize live 
cell imaging in H2B-GFP cells to identify the source of micronuclei in TRRAP/KAT5 
depleted cells. 
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Figure 25. TRRAP/KAT5 depletion is associated with changes in nuclear structure 
and enrichment of SASP genes. 
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(A) DAPI staining of nuclei of HUH7 cells after infection with sgNT, sgTRRAP, 
sgKAT5 and sgTOP2A with yellow arrowheads identifying micronuclei and DNA 
bridges. (B) Quantification of micronuclei in TRRAP, KAT5 and TOP2A depleted 
HUH7 cells.  (C) Quantification of DNA bridges in TRRAP, KAT5 and TOP2A depleted 
HUH7 cells. (D) Heatmap displaying log-2-fold changes in FPKM of SASP genes 
between TRRAP depleted and NT HUH7 cells. Data was presented as mean ± SD; p-
values were calculated by comparing to sgNT, **p < 0.01, ***p < 0.001 (student’s t test).    
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APPENDIX II 
Developing CRISPR tools for cancer research  
Preface 
The work described in this appendix describes two applications of CRISPR 
technology in cancer research. The first application was done in collaboration with Art 
Mercurio’s lab in a study by Elaimy et al (Elaimy, A.L., Sheel,A.,  Brown, C., Walker, 
M., Amante, J., Xue, W., Chan, A., Baer, C., Goel, H., & Mercurio, A. Real-time 
imaging of integrin 4 dynamics using a reporter cell line generated by Crispr/Cas9 
genome editing) that describes generating a fusion protein to study its dynamics in breast 
cancers.  
The second application is in a study by Mou et al (Mou, H., Ozata, D. M., Smith, 
J. L., Sheel, A., Kwan, S. Y., Hough, S., Kucukural, A., Kennedy,Z., Cao, Y., & Xue, W. 
(2019). CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo 
cancer modeling. Genome medicine, 11(1), 21.) that describes utilizing CRISPR to 
“knock-in” an oncogene in order to generate in vivo models of ICC.  
  
Background and Significant Results 
The advent of the CRISPR/Cas9 system has resulted in major advances in the 
field of genome engineering. CRISPR/Cas9 introduces site specific double-strand breaks 
(DSBs) using a programmable sgRNA. These DSB can be repaired via homology-
independent repair, such as non-homologous end recombination (NHEJ), or homology-
directed repair (HDR) with an exogenous homologous DNA template. NHEJ occurs more 
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frequently than HDR and can therefore be utilized to generate knockout cell lines, as 
demonstrated in Chapter II and Chapter III of this dissertation. Moreover, HDR can also 
be used to knock-in desired genes. This function has been utilized to generate models to 
study gene functions however due to the low efficacy of this system the use of 
CRISPR/Cas9 mediated HDR editing has been limited. However, in this appendix I will 
briefly describe two studies that utilize CRISPR to “knock-in” a casette in a cancer 
context.  
In the first study by Elaimy et al. we utilize Comma D1 cells, a murine mammary 
epithelial cell line, to generate cell line that express a TdTomato tagged 4 Integrin from 
its native locus via HDR. In order to generate this cell line, we utilized Cas9 to generate a 
DSB at the end of the last exon in the endogenous 4 Integrin (ITGB4) gene and provided 
a donor plasmid to insert a cassette that containing a mutated stop codon followed by the 
TdTomato cassette (Figure A2.1A). This design allowed for integration of the TdTomato 
cassette at the end of the ITGB4 ORF while simultaneously mutating the stop codon to 
allow for translation of the TdTomato tag. I validated successful integration via PCR 
using primer pairs that both bind inside the tdTomato cassette and flank the cassette at the 
5’ and 3’ genomic locus (Figure A2.1B). Furthermore, I identify four genomic loci as 
predicted off target sites for the sgRNA utilized in this study and demonstrate that there is 
no TdTomato integration at predicted off target sites using the same PCR based approach 
as the expected band size for integration would be ~500bp (Figure A2.1.B). The band in 
OT4 at ~800bp is likely an artifact as integration is not seen in the reverse orientation. 
Alternatively, this band could also represent partial integration of the donor plasmid at 
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this site however this site is an intronic region therefore we would expected no aberrant 
TdTomato protein synthesized from this site.  
While HDR is an invaluable tool that allows for the integration of exogenous 
cassettes, the efficiency of this process is low in vitro (~2%-5%) and cannot be detected 
in vivo without viral mediated delivery (318). Therefore, in the study by Mou et al.(319), 
we attempted to enhance integration of cassettes in vivo using a three-step process 
(Figure A2.2A). The first step utilized an sgRNA and Cas9 to induce a DSB at the target 
DNA locus, in this case Actin. The second step utilized another sgRNA to cut and 
linearize a Circular Donor plasmid which, in the third step, is then inserted into the DNA 
at the Actin locus. Using this system, termed CRISPR-based Somatic Oncogene kNock-
In for Cancer Modeling (CRISPR-SONIC), we demonstrated GFP integration rates of 
~17% in vitro (Figure A2.2B). However in some cell lines, integration of GFP was <1% 
(Figure A2.2C). We demonstrated that this was due to SNPs in the Actin locus near the 
sgRNA binding site (Figure A2.2D). These SNPs reduced the efficiency of cutting in step 
1 of the CRISPR-SONIC process and therefore reduced GFP integration efficiency. 
Overall this data highlighted the importance of sequencing the target region prior to 
sgRNA design as mismatches between the genomic locus and sgRNA can dramatically 
reduce binding of Cas9 to the target locus and therefore reduce cutting efficiency. 
Furthermore, in this study we demonstrated that oncogenes like HRAS can also be 
inserted into this locus in hepatocytes, via hydrodynamic tail vein injection of the 
plasmids, to model ICC in vivo.  
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Overall these two studies highlighted two applications of CRISPR based HDR 
that can aid in the cancer research. Overexpressing fusion proteins in order to study their 
localization and binding partners can lead to false positives as expressing supra-
physiological levels of proteins can alter cellular biology and the protein’s 
functions/localizations/binding partners. By utilizing CRISPR based HDR, we are now 
able to easily tag proteins directly at their endogenous genomic locus and thereby bypass 
the deleterious effects of overexpression. Although HDR has low efficiency in vitro, 
techniques like CRISPR-SONIC can increase integration efficiency by ~15% and allow 
for integration. Furthermore CRISPR-SONIC can be utilized to integrate genes in-vivo 
without the use of transposases and Adeno-Associated viruses (AAVs).  
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Figure 26. HDR Mediated Integration of TdTomato in Comma D1 cell. 
(A) Diagram of the strategy utilized to generate insert a TdTomato cassette at the final 
exon of the ITGB4 genomic locus to generate a TD-Tomato-ITGB4 fusion protein 
TdTomato via CRISPR mediated HDR. (B) Strategy depicting PCR based approach to 
assay for integration at the ITGB4 site and at four off target sites (OT1-OT4). 2% agarose 
gel displaying PCR products at each site. The expected size for successful insertion was 
500bp.     
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Figure 27. CRISPR-SONIC based approach for increased integration efficiency. 
(A) Schematic depicting three step strategy for CRISPR-SONIC based integration. (B) 
Quantification of insertion efficiency of GFP in vitro in Neuro2A cells (C) Flow 
Cytometric analysis of CRISPR-SONIC mediated GFP integration in GreenGo cells. (D) 
Sanger sequencing track of Actin 3’UTRin GreenGo cells highlighting the SNP (red) that 
is in the 3’UTR of this cell line.   
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